header logo image


Page 732«..1020..731732733734..740750..»

Take care of yourself this winter! – The News on Sunday

January 26th, 2020 4:48 am

An unprecedented cold spell has taken over Pakistan and the country, even the safely tropical city of Karachi, has not experienced the kind of chills that it has been suffering this year. In this kind of weather, its understandable that people have chosen to go into hibernation, finding the perfect excuse to stay in bed and not turn up for work. Those who do have to step out of the home have been struggling with warm clothing and temperature control. Fan heaters and inverters have had a lucky run, thanks to the nationwide gas shortage which accompanies harsh winters.

With shorter days and colder weather, amplified by weddings, family reunions and oodles of unhealthy food choices, it tends to get difficult to find the motivation to stay healthy and fit but to counter the general air of overeating and inactivity, there are plenty of wellness tips that may help keep your health on track...

Two-thirds of our body is made of water and therefore, keeping ourselves hydrated is one of the healthiest things to do. Symptoms of dehydration range from headaches to nausea to fatigue but its effects on ones immune system may not always be obvious. If one is hydrated, it keeps mucus membranes moist and, in turn, the immune system functions optimally. The best thing would be to up ones intake of fluids (including of course water), which is incredibly beneficial. Aim to drink at least eight glasses of water a day and see the difference!

Science confirms that poor nutrition impairs the immune response while fresh veggies, fruits, nuts, grains and legumes or pulses are full of immune-boosting properties and antioxidants. It is advisable to eat in season; nature provides fresh, seasonal foods to compensate what our bodies lack at a particular time of the year. For instance, citrus fruits are in season throughout winter and are full of Vitamin C.

Though stress is not always bad, especially when one has a work deadline, studies have linked high stress levels to making a person more susceptible to catching colds and flu. Everyone has a way of coping with and reducing stress; whether its taking a bath, working out, sitting outdoors in the garden or having fun with the kids, do something to unwind. One can also minimize stress by working reasonable hours at their job and using free time to rest and relax alone or with friends and family.

We often overlook the simple things like washing our hands; it is a simple prevention method from germs and diseases. Washing hands regularly with soap for at least 20 seconds, and ensuring they are thoroughly dry, helps control infection. When coughing or sneezing, one should use a tissue and dispose if off. If one becomes mindful of this for a few weeks, it will soon become second nature.

Sleep is essential for ones body to rest, repair and rejuvenate. This is why people look their best after a good nights sleep. The human growth hormone that is released during sleep helps repair ones body at a cellular level besides benefitting the immune system. If one has interrupted or less sleep that the body requires, it significantly reduces the effectiveness of ones immune system; particularly, the natural killer cells which is your bodys first line of defence against germs.

See the article here:
Take care of yourself this winter! - The News on Sunday

Read More...

Study shows high amount of forever chemicals in tap water; local systems respond – WTOP

January 26th, 2020 4:48 am

A new study by an environmental watchdog group finds more drinking water systems containing "forever chemicals," including in the D.C. region.

A new report by an environmental watchdog group finds more drinking water systems around the country than previously believed are contaminated by what the group characterizes as high levels of forever chemicals, which arent broken-down over time.

Water systems in D.C. and Prince Georges County, Maryland, were among those with a high amount of the man-made chemicals, known as perfluoroalkyl substances, or PFAS, according to the Environmental Working Group study.

Of tap water samples from 44 places in 31 states and D.C., only one location had no detectable PFAS, according to the EWG study.

In D.C., the groups testing found 21.7 parts per trillion, while in Prince Georges County, the values were 17.8 parts per trillion.

The advocacy group cites 1 part per trillion of PFAS as a safety threshold.

The Environmental Protection Agency has not set any nationwide limits. However, in a 2016 water health advisory, the EPA recommended a level of no more than 70 parts per trillion, which the agency said offers a margin of protection for all Americans throughout their life from adverse health effects resulting from exposure.

In December, the EPA said it would move forward to study two chemicals that fall under the PFAS umbrella perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFAS) to determine whether it should set a maximum level for those chemicals. The EPA has known about the existence of PFAS in drinking water for almost two decades.

The chemicals, which are used to make carpets, clothing, paper packaging for food, cookware and firefighting materials, have been in use since the 1940s. Exposure to the chemicals over certain limits has been linked to excessive cholesterol levels, ulcerative colitis, thyroid disease, testicular and kidney cancer, and problems in pregnancies, according to the EPA.

John Lisle, of DC Water, acknowledges the utility and scientists are continuing to learn about PFAS chemicals.

Testing in 2014 by DC Water and other local utilities did not detect the chemicals, but the detection threshold was higher, Lisle said. Newer, more precise methods of testing have since been developed to detect very low levels of PFAS.

Still, Lisle said risk to humans is low: The report confirms the PFAS detected in tests conducted in D.C. are at levels well below any established EPA health advisory for these compounds.

The Centers for Disease Control and Prevention, on its website, said the safety risk from PFAS is still unclear: Human health effects from exposure to low environmental levels of PFAS are uncertain. Studies of laboratory animals given large amounts of PFAS have found that some PFAS may affect growth and development, reproduction, thyroid function, the immune system and injure the liver.

Though the environmental advocacy group would like to reduce the amount of PFAS in the nations water, inexpensive home carbon filters, as well as reverse osmosis, and ion exchange water treatment systems appear to be helpful in minimizing risk.

Lyn Riggins, with WSSC Water, which provides tap water in Prince Georges County, said: For more than 101 years, our water has consistently met all Safe Drinking Water Act requirements. In fact, we have never had a single drinking water quality violation in our history.

The [EPA] does not yet regulate PFAS compounds, but maintains a health advisory of 70 parts per trillion for two of the most common compounds, PFOA and PFOS, said Riggins. The EWG analysis reported WSSC Waters total PFAS to be 17.8 ppt, well below the EPAs health advisory.

The Associated Press contributed to this report.

Like WTOP on Facebook and follow @WTOP on Twitter to engage in conversation about this article and others.

2020 WTOP. All Rights Reserved. This website is not intended for users located within the European Economic Area.

Read this article:
Study shows high amount of forever chemicals in tap water; local systems respond - WTOP

Read More...

Oncolytics Biotech: A Small But Very Promising Cancer Player In 2020 – Seeking Alpha

January 26th, 2020 4:48 am

Today, we will study why Oncolytics Biotech (ONCY) is risky but attractive in 2020.

Oncolytics Biotech is a clinical-stage company focused on the development of an intravenously delivered immuno-oncolytic virus called Pelareorep. The company is targeting solid tumors and hematological malignancies. Oncolytics Biotech has partnered with multiple big pharma players such as Pfizer (PFE), Merck (MRK), and Roche Holding (OTCQX:RHHBY) to explore the efficacy of Pelareorep in combination with oncology drugs belonging to different classes, across a range of cancer indications.

On December 6, the company received notice from Nasdaq that it was in compliance with the exchanges minimum bid price requirement.

The global immune checkpoint inhibitors market is anticipated to cross US$ 25 Billion by 2022. Unlike surgery, radiotherapy, and chemotherapy, checkpoint inhibitors do not directly target the tumor cells. Instead, they amplify and accelerate the immune system in the patients body to identify and then destroy the tumor cells.

The market opportunity would have been even higher if immunotherapies would not have failed frequently. A major reason for the failure of immunotherapies stems from the ability of tumor cells to alter the microenvironment and avoid getting identified by the bodys immune system. Cancer cells are not foreign bodies like bacteria and viruses. Hence, the immune system finds it difficult to identify them. Besides, immunotherapies also fail when the patient does not have T-cells. T-cells also require to be at the location of the tumor. There are certain indications where only around 20% of patients are currently benefitting from checkpoint inhibitors.

The immune system is categorized into two types, innate and adaptive. The innate immune system comprises of nonspecific defense mechanisms such as skin, chemicals in the blood, and natural killer cells. This activates immediately or within hours of an antigen's appearance in the body. The adaptive immune system comprises of T-cells, which generate an antigen-specific immune response. Adaptive immunity also involves memory, thereby resulting in improved response to that specific antigen in the future.

To make immunotherapies work, there are three core requirements. T-cells have to be present in the body. These T-cells have to be moved to the location of the tumor. The tumor cells also need to express PD-L1, the target of checkpoint inhibitors. Hence, to make checkpoint inhibitors work, we need to increase the number of T-cells, move them to the location of the tumor, and cause the tumor to overexpress PD-L1.

Oncolytics Biotech is working on Pelareorep, an oncolytic virus that aims to activate the innate and adaptive immune system in the patients bodies. This, in turn, is expected to increase inflammation in tumors, which would cause overexpression of checkpoint inhibitors. This will finally help the immunotherapy to effectively detect the tumor cell.

Oncolytic viruses are retroviruses that replicate only and specifically in tumor cells. Hence, there is no effect on normal tissues. Hence, the goal of oncolytic viruses is to infect and replicate into tumor cells and allow the immune system to identify these tumors.

Pelareoreps genome is double-stranded RNA. The immune system can detect this structure very easily in normal cells. Cancer tissue does not have the ability to identify the double-stranded RNA, thereby allowing the virus to replicate. The companys first patents were based on this understanding of biology.

Pelareorep not only activates the innate immune system to destroy tumor cells but also activates the adaptive immune system. When tumor cells are destroyed by the innate immune systems natural killer cells, it leads to cell debris. Thereafter, the adaptive immune system or T-cells learn to identify the tumor cells based on this debris.

Pelareorep is currently being evaluated in combination with other cancer therapies in metastatic breast cancer, pancreatic cancer, and relapsed/refractory multiple myeloma indications.

Oncolytic Biotech is also developing a biomarker blood test to identify patients most likely to benefit from Pelareorep. In April 2017, the company had reported median OS (overall survival) of 20.9 months in Phase 2 randomized, open-label study in patients with mutated p53 metastatic breast cancer when treated with Pelareorep combined with paclitaxel. This was more than double the OS of 10.4 months seen for patients treated only with paclitaxel. Since the OS benefit is a function of the immune system, the FDA has asked the company to measure the strength of the immune system.

Oncolytic Biotech is using TCR sequencing to evaluate the robustness and reactivity of the patients immune system called T-cell clonality. The biomarker blood test can help evaluate the patients immune reserve and thereby predict the response to this oncolytic virus therapy. Within three weeks, the company can evaluate whether new T-cells are being formed and if the patient is actually responding to therapy.

Oncolytic Biotech has reported the creation of new T-cells and existing T-cells becoming reactive to the tumor for the first early-stage breast cancer patient treated with Pelareorep combined with Roches Holdings Tecentriq in AWARE-1 trial. Unlike normal individuals in an urban setting whose forms 2-3 new T-cell clones every month, the patient had about 450 T-cells. This is a clinical proof of Pelareoreps ability to train the immune system.

The company also demonstrated an increase in T-cells within the tumor as well as at tumor periphery. The company expects to complete enrollment of this study as well as announce interim data in the first quarter of 2020. Oncolytics Biotech also expects final data from this trial in mid-2020.

Oncolytics Biotech, Pfizer, Merck KGaA, and a leading cancer research network, PrECOG, are also studying a combination of Pelareorep, Bavencio, and paclitaxel in three-arm open-label Phase 2 study, BRACELET-1 in metastatic breast cancer indication. The company plans to commence enrollment in this trial in the first quarter and complete enrollment by the fourth quarter of 2020. The company also expects interim data from this trial in the fourth quarter of 2020 and the final data in the first half of 2021.

In May 2018, Oncolytics Biotech received SPA (special protocol assessment) from the FDA for its Pelareorep program in breast cancer indication. FDA recommended the company to identify a biomarker for this therapy before the Phase 3 trial. The agency has also confirmed that only one successful Phase 3 trial will be required for securing approval for this therapy.

In October 2019, the company presented clinical data across 13 clinical studies across various cancer indications, which demonstrated the effectiveness of intravenous delivery for Pelareorep. 81% of the tumors were positive for replicating the virus. Excluding melanoma skin biopsies, the number of tumors with replicating virus was almost 96%.

Pelareorep has demonstrated efficacy in combination with CDK 4/6 inhibitors in early-stage breast cancer indication in pre-clinical studies. The drug is also demonstrating activity in combination with proteasome inhibitor, Amgens (AMGN) Kyprolis (carfilzomib) in an ongoing NCI's sponsored multiple myeloma study. In December 2019, the company announced positive results for a combination of Pelareorep and carfilzomib in multiple myeloma.

Oncolytics Biotech expects interim data from both the above trials in the fourth quarter of 2020.

In November 2019, Oncolytics Biotech announced a partial response of 17.4 months from 1b REO 024 study evaluating Pelareorep in combination with Mercks (MRK) Keytruda in Advanced Pancreatic Adenocarcinoma patients. The partial response has already exceeded the historical overall survival data in this indication. The company is now evaluating this combination regimen in the Phase 2 trial. Oncolytics Biotech expects to complete Phase 2 enrolment by mid-2020 and release final data from the trial in the second half of 2020.

Pelareorep has demonstrated favorable safety and tolerability in these trials.

Oncolytics Biotech has a strong patent estate for Pelareorep, which involves 399 patents worldwide. The composition of matter patent protects the particular strain used in this therapy. This IP estate will protect the therapy from competition till 2028.

Pelareorep scores ahead of other OV (oncolytic virus) therapies in three key aspects of delivery, safety, and efficacy. Unlike other OVs which require intratumoral delivery, Pelareorep is administered intravenously. This will allow nurses to administer Pelareorep with chemotherapy drugs the same way they infuse other cancer therapies. Intratumoral delivery requires specialized training and hence is costlier for the oncologist.

Pelareorep has also been found to target cancer cells across the body, while not affecting normal cells. This systemic mechanism of action is yet to be demonstrated by other OVs. Finally, Oncolytic Biotechs efforts to identify a biomarker for this therapy can help identify patients most likely to benefit from Pelareorep.

Oncolytic Biotechs growth prospects depend solely on the clinical and commercial prospects of its investigational IOV (immuno-oncolytic virus), Pelareorep. This exposes the company to a high degree of business concentration risk. The companys research programs are in Phase 1 or Phase 2 of clinical development.

The probability of final regulatory approval for an asset currently in Phase 1 in oncology indication is only 5.1%. The probability of final regulatory approval for an asset currently in Phase 2 in oncology indication is only 8.1%. Based on these numbers, we see that the company is exposed to a high degree of R&D failure risk.

Oncolytic Biotech has cash of $9.28 million and zero debt on its balance sheet. In the last 12 months ending September 2019, the company spent around $12.9 million cash on operational activities. While the company is scheduled to earn up to 86.6 million from collaborators, these payments are spread over multiple years. Hence, the chances of a possible dilutive round of funding remain high. The company may also raise some debt to fund its operations.

Finally, the company is not yet profitable and may continue to be loss-making for many more years. This can dampen the companys valuations.

On January 2, Roth Capital analyst, Jonathan Aschoff reiterated the Buy rating and increased Oncolytics target price from $6.80 to $9.0. The analyst expects final data from the Phase 2 AWARE-1 breast cancer trial in the second quarter of 2020. In December 2019, Echelon Wealth Partners Douglas Loe reiterated buy rating for the stock and set target price at $8.43. In May 2019, RBC Capital analyst Douglas Miehm maintained an Outperform rating and set target price at $6.89.

The above table highlights the change in analyst recommendations and target price for the stock since December 2018.

Oncolytics Biotech will not have a steady stream of revenues for the foreseeable future. Analysts expect the company to reduce its loss per share in 2020. However, the improvement will most likely be due to additional equity dilution and not a reduction in net losses.

Oncolytic Biotech stands a solid chance of being an acquisition target for big pharma companies. There have already been many licensing and acquisition transactions in the oncolytic virus space.

In this backdrop, I believe the target price of $6.0 is a likely estimate of the company's share price after 12 months. Although a very risky stock, the companys oncolytic virus technology holds huge promise in the oncology space. Hence, I recommend investors with above-average risk appetite to consider this stock in 2020.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Visit link:
Oncolytics Biotech: A Small But Very Promising Cancer Player In 2020 - Seeking Alpha

Read More...

Breakthrough diabetes insulin drug developed with help from Buffalo – Buffalo News

January 26th, 2020 4:47 am

Some people watch what they eat. Paige and Tanner Szczesekhave to watch when they eat.

The two children, ages 6 and 2, from Cheektowaga, have Type 1 diabetes. Like others with their condition, they must take extra insulin before meal and snacks. It takes time to work. Eat too soon, and blood sugar can climb dangerously high a constant worry for their mother, Ashley.

My biggest goal is that my children can just feel like children, she said.

Thanks to a new drug developed with an assist in Western New York, they have more of a chance.

The Food and Drug Administration last month approved of a drug that brings researchers a step closer to developing an artificial pancreas that will provide fast-acting insulin in proper amounts at just the right time for those with diabetes.

Fiasp, made by Novo Nordisk, starts working in 2 minutes, hits full force within 10 minutes and even can be taken shortly after someone withdiabetesstarts eating.

Previous fast-acting insulins took at least two or three times as long to do that job.

The newest drug has been available to adults since 2017, but the Food and Drug Administration wanted testing on children before making it available to them. More than 700 children in 17 countries participated in the clinical trial, including five children ages 13 to 17 who have been patients in the diabetes centers at UBMD Pediatrics and next door at Oishei Childrens Hospital on the Buffalo Niagara Medical Campus.

This was a big commitment for the families, said Dr. Kathleen E. Bethin, a clinical professor in the Department of Pediatrics in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, and a physician at both diabetes centers. The kids were in the study for almost a year. There were a lot of extra blood draws and more blood sugar checks than are typically required.

Fiasp brings diabetes researchers closer to mimicking a closed-loop system that uses a glucose monitor, continuous insulin infusion pump and other technologies to allow people whose bodies dont make insulin to live like those whose do.

The new fast-acting insulin drug Fiasp boosts the prospects for a closed-loop insulin system often referred to as "an artificial pancreas," diabetes researchers in Buffalo and elsewhere say. (John Hickey/Buffalo News)

The goal in the diabetes field is to develop insulin analogs that behave more like natural insulin, which is rapid on, rapid off, meaning its quickly released, then quickly dissipates, said Dr. Lucy D. Mastrandrea, chief of the Division of Endocrinology/Diabetes at UBMD Pediatrics and medical director for the Oishei Childrens Hospital Diabetes Center. Part of the reason this drug was developed was to have a better timeline of action thats closer to natural insulin.

The body breaks down carbohydrates into blood sugar to use for energy. Insulin is a hormone needed to bring glucose from the bloodstream into human cells. When blood sugar gets too low, the process breaks down and can lead to learning challenges, seizures, loss of consciousness and death. When it spikes, especially often and over time, complications include limb amputation, heart and kidney disease, and stroke.

For those without diabetes, the pancreas, liver and other organs work together to automatically and seamlessly produce insulin and adjust levels as needed.

Type 2 diabetes is diagnosed when the body doesnt use insulin properly. It often can be managed through a combination of healthy eating, regular exercise and oral medications. Sometimes, insulin also is needed.

Those with Type 1 diabetes produce no insulin. They need to inject manufactured basal insulin to maintain levels throughout each day, load carbs or take medication when blood sugar levels get too low, and add fast-acting insulin to lower them when blood sugar levels climb.

Nearly 18,000 new cases of Type 1 diabetes are diagnosed each year. The majority of children have Type 1, while the majority of those diagnosed in adulthood have Type 2.

Our goal is to keep them in as best control as possible during their childhood years, so that they're not running the risk of dealing with complications when they're in their 20s and 30s, Mastrandrea said.

Drug-maker Eli Lilly engineered the first human-derived insulin, Humulin, in 1981. The company in 1996 developed a faster-acting insulin, Humalog, which is still routinely used. NovoLog and Apidra are among other brands that can lower blood sugar within 20 to 30 minutes after they are injected through a needle or an insulin pump, said Dr. Paresh Dandona, a leading international diabetes researcher, head of the Western New York Center of Diabetes-Endocrinology in Amherst and distinguished professor and chief of endocrinology, diabetes and metabolism in the UB medical school.

Administering the drugs takes planning and guesswork because eating, exercise, stress, illness and other factors affect blood sugar levels. That means those with diabetes need to predict related dips and spikes well in advance. Mealtimes generally are the most challenging because they can spark pronounced spikes.

The food hits you a lot faster than the insulin does, said Szczesek.

Fiasp changes the equation. The newer formulation of NovoLog includes niacinamide (vitamin B3) to boost the speed of absorption.

There still is a lag, but it's the best thing we have, said Dandona, whose clinic helped with adult trials several years ago and who has prescribed the drug to some of his patients during the last two years, with good results.

Paige Szczesek, 6, of Cheektowaga, looks at her personal diabetes manager, which helps her and others more closely track her blood glucose levels and insulin use. (John Hickey/Buffalo News)

Paige and Tanner Szczesek are on the front end of the learning curve when it comes to keeping a proper balance. Their father, Shane, also was diagnosed as a child with Type 1 diabetes.

Greater speed is a godsend for the children, each of whom has a continuous glucose monitor and insulin pump to help control their blood sugar. Paige also has a personal diabetes manager, as part of her pump, that helps her family determine when she needs more insulin and how much. Sweet treats are always on hand for times when their blood sugar drops.

When she needs more fast-acting insulin, someone needs to decide when to administer it, then see how it's working. Ashley Szczesek uses a smartphone to keep tabs on blood glucose levels for both children. She teams up with Paiges school nurse and teachers to address shortfalls and spikes. There are phone calls or text messages every time blood sugar readings warrant, as well as reports about when and what the first-grader has eaten.

I can't just send my kid into school and say, I'll see you at the end of the day,' Ashley Szczesek said. I have an alarm set on my phone for when they're high or they're low. On top of that, especially during the night, I'll normally set several alarms to get up and check their blood sugars. If they're low, I go wake them up and give them something to bring up their blood sugar. If they're high enough, I give them some extra insulin. Between us as parents and the children, there's a lot of sleep loss."

Paige started using Fiasp last year after the clinical trial ended. Mastrandrea prescribed it off-label. Her brother started taking it a few weeks ago.

Paiges A1c level has dropped by 1 percent, to about 7 percent, higher than those without diabetes but in a good range for someone Paiges age with the condition.

Fiasp can ease the diabetes burden, but not erase it.

Those without adequate health insurance may be unable to cover higher co-pays or other out-of-pocket costs. Some people have not wanted to switch for that reason, Mastrandrea said.

Meanwhile, researchers continue to pursue a biologic cure, as well as an insulin pump that works with a continuous glucose monitor to deliver insulin on a minute-by-minute basis as needed.

In order to do that really well, Mastrandrea said, you want to have insulins that are faster-acting, absorb better and behave the way my pancreas does. Fiasp is in that category.

Some of Dandonas patients already have the most advanced insulin pump, the Medtronic 670G, though the device can be complicated for most adults to use, let alone children, he said, and still needs agents to more quickly bring blood sugars into the balanced range.

Still, for those in the field and for families like the Szczeseks, recent progress has been nothing short of remarkable.

Early prototypes of closed-looped models like the 670G once weighed two to three times that of adult patients, Dandona said, and now we have a tiny device doing the same thing.

Excerpt from:
Breakthrough diabetes insulin drug developed with help from Buffalo - Buffalo News

Read More...

Global diabetes devices market is expected to grow with a CAGR of 6.7% over the forecast period from 2019-2025 – Yahoo Finance

January 26th, 2020 4:47 am

The report on the global diabetes devices market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global diabetes devices market to grow with a CAGR of 6.

New York, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Diabetes Devices Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025" - https://www.reportlinker.com/p04947545/?utm_source=GNW 7% over the forecast period from 2019-2025. The study on diabetes devices market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on diabetes devices market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global diabetes devices market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porters five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global diabetes devices market over the period of 2017 to 2025. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings1) Drivers Growing prevalence of diabetes Rapidly changing lifestyles Rising occurrence of obesity2) Restraints Low awareness about diabetes management and monitoring devices3) Opportunities The introduction of advanced insulin delivery devices

Research Methodology

A) Primary ResearchOur primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include1. Key Opinion Leaders associated with Infinium Global Research2. Internal and External subject matter experts3. Professionals and participants from the industry

Our primary research respondents typically include1. Executives working with leading companies in the market under review2. Product/brand/marketing managers3. CXO level executives4. Regional/zonal/ country managers5. Vice President level executives.

B) Secondary ResearchSecondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include1. Company reports and publications2. Government/institutional publications3. Trade and associations journals4. Databases such as WTO, OECD, World Bank, and among others.5. Websites and publications by research agencies

Segment CoveredThe global diabetes devices market is segmented on the basis of type of devices, and end user.

The Global Diabetes Devices Market by Type of Devices Monitoring Deviceso Self-Monitoring Blood Glucose (SMBG)o Continuous Blood Glucose Monitoring (CGM) Treatment Deviceso Manual Injectiono Pumps

The Global Diabetes Devices Market by End User Diagnostic Centers Hospitals Home Care Ambulatory Surgery Centers

Company Profiles Abbott Laboratories F. Hoffmann-La Roche Ag Johnson & Johnson (LifeScan, Inc.) DexCom Inc. Bayer Corporation Arkray, Inc. Sinocare, Inc. Medtronic PLC Sanofi Novo Nordisk Eli Lilly and Company Other companies

What does this report deliver?1. Comprehensive analysis of the global as well as regional markets of the diabetes devices market.2. Complete coverage of all the segments in the diabetes devices market to analyze the trends, developments in the global market and forecast of market size up to 2025.3. Comprehensive analysis of the companies operating in the global diabetes devices market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.Read the full report: https://www.reportlinker.com/p04947545/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Link:
Global diabetes devices market is expected to grow with a CAGR of 6.7% over the forecast period from 2019-2025 - Yahoo Finance

Read More...

Can you ‘catch’ heart disease, cancer, and diabetes? – Medical News Today

January 26th, 2020 4:47 am

A recent paper outlines an intriguing new theory. The authors ask whether the microbes that inhabit the human body could transfer diseases such as diabetes and heart disease from person to person.

The importance of the microbiome is currently at the forefront of scientific discourse. Experts and the public are equally absorbed by the fascinating influence of microbes on human health.

A new theoretical paper, published in the journal Science, takes the discussion one step further. The authors ask whether conditions such as cardiovascular diseases, cancer, and chronic respiratory illnesses could be transmitted from one individual to another via the bacteria, fungi, and viruses that live on and in us.

The paper, which is titled Are noncommunicable diseases communicable? is likely to spark lively debate and a glut of new research. Because scientists now believe that the microbiome plays a role in many diseases, the authors ask whether it could also play a part in transmitting diseases among individuals.

Heart disease, cancer, and lung conditions are called noncommunicable diseases (NCDs) because they result from genetic, environmental, and lifestyle factors: Therefore, they cannot be passed from person to person.

Over the last 100 years, mortality rates from communicable diseases, caused by infectious microbes, have fallen dramatically. During the same period, mortality rates from NCDs have risen sharply, now accounting for 71% of deaths globally.

Researchers have demonstrated that changes in the microbiome accompany a wide range of diseases, including diabetes, Parkinsons disease, heart disease, and cancer.

At the same time, scientists have found that the composition of our microbiome appears to mirror those of the people we live among.

For instance, the paper explains that unrelated people who live together have more similar gut bacteria than close relatives who live apart. Scientists currently believe that this similarity results from the shared diet and environment of people who cohabit; but could there be more to it?

The authors of the current paper synthesize these ideas; they explain that Some NCDs could have a microbial component and, if so, might be communicable via the microbiota. This would make NCDs communicable.

As it stands, evidence for this brave new theory is circumstantial, but it certainly merits further scrutiny.

The authors refer to a study of 12,067 individuals that spanned 32 years and report that Having an obese friend was associated with a 57% higher chance of being obese, and there was a 40% higher chance of obesity if a sibling was obese.

Once again, this association could be due to diet, environment, and genetics. Friends and siblings may be more likely to live in similar locations and eat similar foods. But aside from shared behaviors, the authors of the present paper wonder whether individuals might pass along certain microbes that increase the risk of developing obesity.

Obesity is a risk factor for type 2 diabetes, and if we suppose that obesity is transmissible from our microbiome to anothers, it would imply that diabetes could also be considered a communicable disease.

Of course, this is a theory based on a theory, and there is only circumstantial evidence to back it up. As an example of this evidence, the authors explain that Within a year of a [type 2 diabetes] diagnosis, spouses have a higher chance of developing [type 2 diabetes], and this trend remains over 3 years after the initial diagnosis.

Again, this could just as easily be explained by two people sharing an environment and dietary habits.

More convincingly, the authors refer to results of various studies that have found that transferring feces from one mouse with a certain disease to another mouse without that disease can cause the second animal to develop the illness; they write:

[Fecal microbiota transplant] of dysbiotic microbiota from individuals with various NCDs into healthy animals results in disease, such as [cardiovascular disease, irritable bowel disorder, type 2 diabetes], and many others.

In short, the authors explain that disturbances in the microbiome can produce disease and that when scientists transplant these microbial communities into another animal, that animal becomes sick. They continue:

These observations suggest that the microbiota could be a causal and transmissible element in certain diseases that have been traditionally classified as NCDs.

This theoretical road may run both ways, too; the authors outline how transmissible microbiota, especially early in life, may also have a protective role against NCDs.

To date, bacteria are the most studied components of the microbiome, but it is possible that viruses which outnumber resident bacteria could also play a role in making NCDs transmissible.

As the authors write, scientists will need to carry out specific research to prove whether NCDs can, in fact, be communicated. Distinguishing between the effects of environment and any effects of microbial transfer will be challenging indeed.

This recent paper, however, is not meant to convince us that gut bacteria are transferring NCDs throughout the population. The authors simply hope that their hypothesis stimulates additional discussion and research. It is sure to do just that.

Read more here:
Can you 'catch' heart disease, cancer, and diabetes? - Medical News Today

Read More...

The Connection Between Type 2 Diabetes and Alzheimer’s Disease – A Sweet Life

January 26th, 2020 4:47 am

Its often said that Alzheimers disease is the medical condition people fear mosteven more than cancer. This is understandable, considering the staggering statistics around Alzheimers and the fact that, at least so far as we currently know, there are no truly effective treatments and no cure. (According to the Alzheimers Association in the US, between the years 2000 and 2017, deaths from Alzheimers disease (AD) increased 145%,1 while deaths from other noncommunicable conditions, such as heart disease, actually decreased. In the US alone, approximately 5.8 million people are living with Alzheimers, and this is projected to more than double to about 13.8 million people by 2050.)

Alzheimers may seem mysterious, and the lack of progress toward treatments has been disheartening, but a robust body of scientific evidence suggests that this illness may be a metabolic condition rooted in dysregulated glucose metabolism and insulin signaling.2,3 With this in mind, lets take a closer look at the connections between type 2 diabetes and Alzheimers.

Alzheimers disease is sometimes referred to as type 3 diabetes and has also been described as brain insulin resistance.4,5 In fact, associations between metabolic syndrome (a.k.a. insulin resistance syndrome6) and cognitive impairment are so strong that researchers have coined the term metabolic cognitive syndrometo emphasize these links.7,8,9 The primary malfunction in the brain of someone afflicted with AD is that neurons in affected regions lose the capacity to metabolize glucose properly.10,11 Being unable to harness energy from glucose, these cells atrophy and wither, and the resulting breakdown in neuronal communication may be what leads to the memory loss, cognitive impairment, personality changes, and other hallmarks of the illness.12

Weve known since the research of Rosalyn Yalow in the 1960s that T2D is a disease of too much insulin (unlike type 1 diabetes in which there is not enough insulin). Many researchers believe T2D is the final stage of chronically elevated insulin. Another factor affecting proper insulin secretion and development of type 2 diabetes is the accumulation of fat in the pancreas. (Compromised liver function resulting from the buildup of fat in the liver is called non-alcoholic fatty liver disease, or NAFLD. The analogous condition in the pancreas is non-alcoholic fatty pancreas disease15, although it is not as widely recognized as NAFLD.) Abnormal accumulation of fat in the pancreas may interfere with healthy beta cell function and insulin secretion, and is associated with increased risk for type 2 diabetes and metabolic syndrome.16,17,18

In some people, chronically elevated insulin can precede a T2D diagnosis by a decade or more. Theres a parallel in Alzheimers: in people at risk for AD, reduced brain glucose metabolism is measurable when theyre in their 30s and 40s.19 At this young age, though, they are cognitively healthy and show no signs or symptoms of AD. Even though the brains energy supply from glucose is already compromised, the brain is able to compensate and overcome this fuel shortage. Its only when the damage is so severe and widespread and the brain is no longer able to compensate that problems with cognition and memory begin to manifest.

Turning back to T2D, for many people, the elevated fasting blood glucose or A1c that would trigger a diabetes or pre-diabetes diagnosis is a late developmentin the disease process. Chronically high insulin preceded this for some length of time, going undetected because measuring insulin levels is not a routine part of a checkup or standard bloodwork. In the same way, its possible that the memory problems and cognitive impairment associated with AD are late developments, becoming apparent after years or possibly decades during which the brain has suffered from a progressive decrease in energy.20

Disruptions in either the supply of fuel to the brain or the brains ability to usethis fuel can have catastrophic consequences for cognitive function. The brain accounts for just 2% of a typical adults body weight, but it consumes as much as 20-25% of the bodys glucose and oxygen:

Given the high energy requirement of the brain and its critical dependence on the delivery of a constant supply of fuel, the consequences of leaving such an energy shortfall untreated can be dire. When the brains energy supply is insufficient to meet its metabolic needs, the neurons that work hardest, especially those concerned with memory and cognition, are among the first to exhibit functional incapacity (e.g., impairment of memory and cognitive performance).21

People with type 2 diabetes have an increased risk for Alzheimers disease and other types of dementia compared to those without diabetes.22,23,24 However, even in the absence of high blood sugar, people with chronically high insulin are also at greater risk for AD. In fact, one study showed that risk for AD was highest among people with elevated insulin but who were notdiabetic.25 In a study of subjects with newly diagnosed T2D or pre-diabetes who had seemingly normal cognitive function, greater insulin resistance was associated with reduced brain glucose metabolism and subtle cognitive impairments.26 Its possible that hyperinsulinemia and a disruption in brain fuel usage are the first dominos to fall in the Alzheimers cascade, setting the stage for future cognitive decline.

An interesting point to note is that while elevated insulin in the bloodappears to be a major risk factor for AD, many AD patients havelowerthan normal insulin levels in the brain.27,28 Insulin is not required to transport glucose across the blood-brain barrier, nor for neurons to take up and use glucose. However, insulin receptors are scattered richly throughout the brain, and insulin is believed to play a role in facilitating healthy cognition and the viability and proper functioning of neurons.29,30

Chronically elevated blood glucose and/or insulin have negative impacts on nearly every organ and tissue system in the body: the eyes, the kidneys, the skin, the liver, the ovaries, the prostate gland, nerve cells, and more. The brain is no less susceptible to the detrimental effects of deranged glucose metabolism. In fact, owing to its high energy demands, it might even be moresusceptible than other parts of the body, and Alzheimers disease could be the most severe manifestation of this.

Written by Amy Berger, MS, CNS

Amy Berger, MS, CNS, is a U.S. Air Force veteran and Certified Nutrition Specialist who specializes in using low-carbohydrate and ketogenic nutrition to help people reclaim their vitality through eating delicious foods, and showing them that getting and staying well don't require starvation, deprivation, or living at the gym. Her motto is, Real people need real food! She blogs atwww.tuitnutrition.com, where she writes about a wide range of health and nutrition-related topics, such as insulin, metabolism, weight loss, thyroid function, and more. She has presented internationally on these issues and is the author ofThe Alzheimer's Antidote: Using a Low-Carb, High-Fat Diet to Fight Alzheimers Disease, Memory Loss, and Cognitive Decline.

Read the rest here:
The Connection Between Type 2 Diabetes and Alzheimer's Disease - A Sweet Life

Read More...

South Texas Juvenile Diabetes Association helping families struggling with the disease – KVEO-TV

January 26th, 2020 4:47 am

MCALLEN, Texas Just a day before Matthew Garrett and his family were to celebrate his 3rd birthday, matthew became lethargic and was not himself. Even wanting to cancel his Chuck E. Cheese birthday party. It was the weekend so his parents researched his symptoms online.

Harlan Garrett, Matthews father, We really didnt like what we were reading. We didnt tell each other because we were really hoping and praying that we were wrong.

First thing on a Monday morning a visit to his pediatrician showed Matthew had a blood sugar reading of 654.

He goes your son had diabetes. Ive already contacted the hospital we have a room ready for him to go in there. You do not go home, you do not go get clothes. Said Harlan Garrett.

Matthew had Type 1 Diabetes and it took 8 days to stabilize him, leaving his parents time to wonder what they did wrong. Harlan Garrett says after leaving the hospitalhe was lost and wanted answers. The answers would from the South Texas Juvenile Diabetes Association.

Debra Franco, Executive director, STJDA, We work really hard to work with our local hospitals to make sure that families know upon diagnosis that they are not alone in their journey. That theres a local organization thats there for them.

Debra Franco says the organization was born out of sheer need. It was founded 8 years ago after her own son was diagnosed with Type 1 Diabetes and sent to Driscoll Childrens Hospital in Corpus Christi for treatment. She said there were no doctors or hospitals in the Valley who could treat him.

Its just really frightening not to have a support system when you have a child that has been diagnosed with a chronic disease. Said Franco.

The organization is often the first resource for parents through programs like the Shot Spot Bears Program. With Type 2 Diabetes on the rise with children in the Valley, educational outreach programs like Stomp Out Diabetes, which reached more than 22,000 children.

Felipe Salinas, Board President STJDA, Families receive that box along with helpful literature books to get them started in the journey and a form they can fill out asking them for information so they can reach out to them.

Matthew Garrett is now 5 and has his diabetes under control. Thanks to a monitor which test his blood sugar every five minutes sending a notification to his parents smartphone.

Matthews doctor says his diabetes stems form a virus which attacks cells in his pancreas blocking it from producing insulin.

Harlan Garrett says he cant say enough good things about STJDA and all the support his family has received.

Franco adds, We are there to support families. We ourselves are families dealing with this disease. The compassion is there, the empathy is there and the support system is there.

Thanks to the work the South Texas Juvenile Diabetes Association does, there are now three pediatric endocrinologists in the Valley and every hospital can now treat children with diabetes.

Follow this link:
South Texas Juvenile Diabetes Association helping families struggling with the disease - KVEO-TV

Read More...

Two Innovative Wearables Took Diabetes Control to the Next Level at CES 2020 – HealthTechZone

January 26th, 2020 4:47 am

With 2019 being such an environmentally-focused year. It is no surprise that this years CES 2020 was focused on renewable energy, but it didnt stop there. Health technology is always an important sector at CES 2020. There were two wearable devices that allow diabetics to control their glucose levels through non-invasive methods in a new, innovative way. There are advantages for users, but they also have their limitations.

The Add Care Glutrac

The Glutrac by Add Care aims to provide non-invasive continuous glucose monitoring. Considering that more than 29 million people in the United States have diabetes, the Glutrac hasnt fully made good on their promise to do so.

While achieving the level of accuracy not only helps a person monitor their glucose levels without pricking their finger, it provides the data you need at any given moment. Currently only the thing that is close to this are sensors that enter interstitial fluid, which require a small amount of penetration. The watch claims to be able to detect glucose levels from just optical sensors. Add Care, which is a company from Hong Kong, needs to prove the upmost accuracy to get approved by the FDA.

The goal of Glutrac is to monitor blood sugar without pricking your finger to get blood. These new technologies use artificial intelligence to estimate the persons glucose levels. In its early stages, this technology could expect to see more of these products at CES.

Basically the Glutrac is a smartwatch that will measure blood sugar. It watches your vital signs, including heart rate and uses AI to calculate glucose. According to the site MoneyPug, which is known as a platform to find the best health insurance, the watch has sensors on the back of the watch that can record health data every 15 minutes, providing data on where your blood sugar is at interminably. Furthermore there is a sensor to watch where you can take on-demand readings. The process takes about one minute to measure and analyze in the cloud and deliver measurements.

AerBetic

Believe it or not, dogs can smell when your blood sugar is fluctuating. AerBetic was designed a device using this idea. Not only can this help you recognize the pain and expense of traditional diabetes management, it can help you keep track of your glucose levels. For a while there has needed to be a change in the way we approach diabetes. AerBetic uses the latest gas-sensing technology to create a truly non-invasive, affordable, and wearable diabetes product.

AerBetic is a non-invasive wearable diabetes monitor that continuously provides your blood sugar levels. It also comes with an application that allows the user to set up alerts in order to communicate to a network of health care providers.

To monitor the changes in blood sugar levels, the AerBetic uses a nano sensor that detects gases humans emit. Scientists have identified that this can be an early indicator of conditions such as hypoglycemia or hyperglycemia.

Nano sensors are the core technology of the AerBetic. These devices are customized to the application. The sensors acts like a dogs nose, and it has the ability to sense multiple gases simultaneously. These low detection levels are necessary to monitor your blood sugar.

Health & Tech

Like renewable energy, the health industry is going to be revolutionized by technology. There is seemingly no end to the innovations that technology will provide for health and health care. As the health of our world continues to fluctuate with foods full of sugar and fat and we exercise less and sit at our desks. With such a pervasive disease like diabetes, new technologies are essential.

Despite that renewable energy and eco-friendly products took center stage at CES 2020, health will continue to be a focus of the conference. Not only is creating a closed loop insulin dispenser a key issue for diabetes, these non-invasive wearables will sense when your blood sugar is fluctuating. Diabetes isnt the only disease that could be facilitated by technology, the whole industry will change as new technologies like these become more commonplace. It will continue to be a focus of the CES conference, just like renewable energy products.

Read more here:
Two Innovative Wearables Took Diabetes Control to the Next Level at CES 2020 - HealthTechZone

Read More...

Genetics and lifestyle can be obesity risks – Coshocton Tribune

January 26th, 2020 4:44 am

Emily Marrison, Columnist Published 11:00 a.m. ET Jan. 25, 2020

For better and for worse, we all inherit particular characteristics from our parents.

Maybe its our mothers eyesor maybe our fathers temper. Some of that is directly the result of the DNA weve receivedand some of it comes from the influence they exerted in our environment.

Emily Marrison(Photo: Submitted)

When it comes to our health and wellness, it can be challenging to determine whether nature or nurture has more of an impact. In some cases, it may not really matter. But when it causes you to feel powerless or apathetic about how much you can change your condition, it definitely matters.

Results of a long-term study were recently published in the Journal of the American Medical Association of Cardiology. The study tracked data on more than 2,500 Americans who were followed for decades from young adulthood in 1985 to 2010. One of their findings is that body mass index (BMI) in youth appears to be the best predictor of long-term obesity risk.

There have been other studies in recent years that have identified certain genes that are believed to be responsible for a person becoming overweight and obese. There are rare inherited causes of obesity, but this is not the case for the majority of the population. This study suggests that daily lifestyle is the more important factor for determining our weight.

When we look at the BMI of children, this is showing the result of genetics as well as environment. The genes we inherit can certainly make us more susceptible to weight gain, but that doesnt mean it is inevitable. Hopefully, this research can empower people to know that being obese doesnt have to be someones destiny. Their healthy lifestyle choices the foods they eat, their portion sizesand physical activity can result in a better quality of life.

According to the National Heart, Lungand Blood Institute, being overweight or obese increases your risk of developing heart disease, high blood pressure, type 2 diabetes, gallstones, breathing problems and certain cancers. A European study linked obesity to a nearly six-fold increased risk of developing type 2 diabetes.

If you are looking for ways to learn more about healthy lifestyle choices while managing diabetes, theOSU Extension has some great resources available. I am pleased that we will be partnering with the Coshocton Regional Medical Center this April to offer Dining with Diabetes. This is a cooking school and nutrition education program designed for people with diabetes and their family members or caregivers.

Dining with Diabetes will be held from 5:30 to 7:30 p.m. Mondays April 6 to 27 at Coshocton Regional Medical Center, 1460 Orange Street, Coshocton. The cost of the program is $20 per person and includes all four classes, educational handoutsand small-sized meals that feature a variety of recipes. You are encouraged to also register a support person to attend with you for an additional $5. You can find more details and registration information at coshocton.osu.edu.

Today, Ill leave you with this quote from Billy Graham, When wealth is lost, nothing is lost; when health is lost, something is lost; when character is lost, all is lost.

Emily Marrison is an OSU Extension Family & Consumer Sciences Educator and may be reached at 740-622-2265.

Read or Share this story: https://www.coshoctontribune.com/story/news/local/2020/01/25/genetics-and-lifestyle-can-obesity-risks/4562639002/

See the article here:
Genetics and lifestyle can be obesity risks - Coshocton Tribune

Read More...

Study sheds light on the genetics of hibernation – Scope

January 26th, 2020 4:44 am

When ground squirrels hibernate, their body temperatures drop dramatically -- roughly from 98.6 to 39.2 degrees Fahrenheit for weeks at a time.They also stop eating and enter into a state of torpor to conserve energy; their baseline physiology -- including metabolic, respiratory and heart rates -- slows to approximately 1-3% of normal function.

Arousing from that torpor and returning to their normal temperatures is an intense process akin to a heart attack, as the ground squirrels' heart rates essentially skyrocket so they can rewarm in just a couple of hours. Yet the squirrels emerge from hibernation undamaged and even protected from some conditions that are harmful to humans, such as heart attack and stroke, bone and muscle atrophy and metabolic diseases.

Though environmental factors, such as day length and temperature, influence when ground squirrels begin hibernation, individual genes also affect their behavior. In a recent paper published in Communications Biology, Stanford researchers Katharine Grabek, PhD, Carlos Bustamante, PhD, and their colleagues made strides in pinpointing the role of genetics in driving these large shifts in behavior and physiology -- insights that Grabek said could potentially be helpful in understanding humans.

"To hibernate, we think ground squirrels are using common mammalian genes shared with humans, but they are just utilizing them differently," she told me. "By identifying these genes, we can find new therapeutic avenues for human diseases."

To investigate, Grabek, Bustamante and their team took liver samples from 153 squirrels that were shipped to them by an OshKosh, Wisconsin breeder. They determined the genotype of each, and charted the familial relationships among the animals.

Then the scientists recorded the first day each subject's body temperature dropped, signaling the onset of hibernation. From there, they looked for patterns connecting the timing of hibernation with certain gene variants. They also applied a genome-wide association study -- which provided information about genetic mutations throughout each squirrel's genome to identify which genes statistically were most likely to be associated with the onset of hibernation.

The researchers found that hibernation onset in ground squirrels is strongly governed by genetics -- that is, after accounting for known environmental factors, the remaining differences in when squirrels started hibernation were due solely to genetic variation. The team also identified two genetic variants near FAM204A and EXOC4 -- both are genes shared with humans -- that are most likely responsible, as squirrels with these two mutations in their DNA went into hibernation later in the year than squirrels without the mutations. Twelve other variants also are likely associated with the onset of hibernation, according to the study, but the statistical values were not strong enough to be conclusive.

Grabek told me she was surprised by the definitive nature of the results: "I was expecting that there would be a genetic component explaining some of the variation in hibernation onset," she said, "I just didn't expect so much of variation in timing to be due to genetics."

Identifying genes behind the controlled process of torpor and hibernation could ultimately help scientists understand and develop treatments for conditions and diseases in humans, Grabek told me:

For example, prior to hibernation, the squirrels spend most of their days eating food and accumulating a lot of body fat. Then at the onset of hibernation, they stop eating altogether and, instead, use their fat reserves as a fuel source while they hibernate. Since the genes controlling this dramatic shift in food intake are likely shared with humans, after we identify them in squirrels, the human forms of the genes could be targeted with drugs to help people lose weight.

Other insights from the genes could help researchers formulate treatments to help people recover from heart attacks or strokes, or to maintain muscle mass during prolonged bouts of bed rest, she said.

Bustamante shares Grabek's excitement. He told me, "We believe this is the first of many insights that can be gleaned from studying the molecular basis of mammalian hibernation. Ultimately, we want to see this work translated into medicines and other therapies for the benefit of humankind."

Photo of a ground squirrel from the study, courtesy of Bryan Roeder and Sandra Martin

See more here:
Study sheds light on the genetics of hibernation - Scope

Read More...

Is the consumer genetics fad over? – MIT Technology Review

January 26th, 2020 4:44 am

The CEO of 23andMe told CNBC her company will lay off 100 people as sales of its direct-to-consumer gene tests slump.

This has been slow and painful for us, CEO Anne Wojcicki told the website, which estimated the cuts would pare about 15% of the company's staff.

Boom times: Sales of DNA tests that tell people their ancestry and health facts started booming a few years ago, propelled by TV and Internet ads hawking the promise that people could gain unique insights from their genes.

During 2018, the total number of people who had ever bought the tests doubled, swelling the databases of 23andMe, Ancestry, and several smaller companies to over 26 million people altogether.

The bust: Now, all signs are that sales of the $99 consumer tests slowed dramatically in 2019.

Our own calculations suggest the largest companies sold only four to six million of them, meaning the databases would have grown by just 20% during the year. That would have been the slowest growth rate for the DNA test industry ever.

Uncertain causes: It's not clear why consumers stopped buying tests in droves. It could be that the market is tapped out, and there aren't many people left curious to learn what percent French or Nigerian they are, or whether they are at risk for going bald.

Others may have concerns about their DNA data staying private, since police have started accessing smaller ancestry databases to carry out genetic manhunts.

Ancestry, which maintains the largest database with more than 16 million people, did not answer questions about whether it had seen a sales slowdown. Last year, Ancestry introduced new health offerings in what some analysts saw as a bid spark a "re-testing" market, or coaxing consumers to pay for an additional test.

Read more here:
Is the consumer genetics fad over? - MIT Technology Review

Read More...

Children’s graves reveal genetic diversity of ancient West Africa – Cosmos

January 26th, 2020 4:44 am

By Dyani Lewis

Remains from an ancient gravesite in Cameroon have opened a window into the world of the people who lived in western central Africa before farming and herding became widespread.

Africa is the ancient homeland of our species, and the genetic diversity across the continent is unmatched anywhere else on the planet, yet only a handful of sites bearing human fossils have successfully yielded ancient DNA, which is essential for grasping the genetic make-up of prehistoric Africans.

DNA rapidly degrades in tropical conditions and burials were rare prior to the Iron Age, which started around 1500 BCE in Africa.

There's a tremendous amount of genetic diversity in the past in Africa that we have not been able to see by sampling modern populations, says archaeologist Mary Prendergast from Saint Louis University, Spain, one of the lead authors of a paper in the journal Nature.

Thats where the Shum Laka rock shelter comes in. The site, which lies in the Grassfields region of western Cameroon and bears clear signs of use by human foragers from as long as 30,000 years ago, is unique, says Prendergast.

Eighteen people, mostly children, were buried there during two periods 8000 and 3000 years ago respectively. Both communities were hunter-gatherers, and by the later time period they were using pottery and relying heavily on fruit picked from nearby forest trees.

These time points book-end an important transition period from the late Stone Age to the Iron Age, says Prendergast, during which humans took up farming and herding.

Linguists have also long thought that the Grassfields region could be the birthplace of the Bantu language group. Bantu languages spread across sub-Saharan Africa from about 4000 years ago and are today spoken by more than a third of Africans.

There's been a century of discussion about where Bantu languages originated and how they spread, says Prendergast.

Mark Lipson, from Harvard Medical School, and colleagues extracted then analysed ancient DNA from the DNA-rich inner ears of four children buried at Shum Laka two from each period to see whether they were the ancestors of modern-day Bantu speakers.

But that turned out not to be the case. None of the children who were all related to each other were related to present-day Bantu speakers.

Instead, they were part of a population that has almost been completely replaced. About two-thirds of the Shum Laka ancestry is from a previously unknown line that is distantly related to present-day West Africans. The other third is from a lineage related to present-day central African hunter-gatherers.

Bantu languages may still have their origins in the Grassfields region, says Prendergast, but the Shum Laka children arent part of that ancestral population.

Lipson and his colleagues also used the ancient genomes of the four children, along with genomes from modern-day Africans, to cast their focus much further back in time.

An adolescent male from the rock shelter carried a rare genetic variant of his Y chromosome that is today found almost exclusively in western Cameroon, close to Shum Laka.

A previous study proposed southern Africa as the homeland of the oldest human lineage, but the rare Y chromosome suggests that a lineage contributing to central African hunter-gatherers is just as ancient, cleaving off from other African branches some 250,000-200,000 years ago.

At the time of the split, four lineages emerged. Three are ancestral to present-day central African hunter-gatherers, southern African hunter-gatherers, and all other modern humans. The fourth, a previously unknown ghost population, contributed a small amount of ancestry to both western and eastern Africans.

Another split occurred around 80,000-60,000 years ago, leading to genetic lines that are present in the majority of present-day eastern and western African and all non-Africans.

Compared to Europe or Asia, African ancient DNA studies are in their infancy.

It's incredible what we've learned in the past few years, says Prendergast. But, she adds, we're just scratching the surface of what the human landscape would have looked like before the spread of food production.

See original here:
Children's graves reveal genetic diversity of ancient West Africa - Cosmos

Read More...

Environmental and genetic determinants of plasmid mobility in pathogenic Escherichia coli – Science Advances

January 26th, 2020 4:44 am

INTRODUCTION

The spread of antibiotic resistance is outpacing the development of new antibiotics. On average, new antibiotics cost upward of $500 million USD and take 10 years to develop, only to have widespread resistance appear in less than 3 years (1, 2). Horizontal gene transfer (HGT) is often implicated in this rapid decline in efficacy, mobilizing reservoirs of resistance long established in the environment by natural antibiotic producers (3). In this way, targeting mobilization to restore antibiotic efficacy may be more successful than trying to eliminate resistance outright (4, 5).

Conjugation, the direct transfer of DNA from a donor to a recipient, is considered the HGT mechanism most responsible for mobilizing resistance among Enterobacteriaceae (2, 6). Conjugative plasmids are exchanged across broad host ranges, harbor resistance to virtually all antibiotics, and may be maintained in hosts with little cost, or in spite of costs, to fitness (7, 8). Furthermore, resistance genes tend to cluster on plasmids, allowing acquisition of multidrug resistance in a single transfer and making antibiotic selection for one now select for all (2).

Modulating conjugation to curtail the spread and maintenance of resistance requires an understanding of the environmental and genetic factors underlying plasmid mobility. Multiple factors have been proposed, including nutrient levels (9, 10), cell-cell signaling (1113), and even antibiotics (11, 1417), potentially accelerating the spread of resistance. Entire environments (e.g., animals, sewage, and biofilms) have also been labeled conjugative hotspots, uniting compatible donors, recipients, and plasmids under conditions that encourage HGT (6). However, growth dynamics are often coupled with conjugation modulation, making conjugation-specific effects difficult to interpret (Fig. 1A). For instance, in contrast to the prevailing conclusion that antibiotics promote conjugation, a recent study found no notable antibiotic effects when controlling for growth dynamics (9). Together with limited strain diversity and low-resolution genomic analysis, this ambiguity in conjugation quantification leaves the determinants of plasmid mobility in question.

(A) The influence of environmental and genetic factors on conjugation is confounded by growth dynamics between donor (red), recipient (blue), and transconjugant (purple) populations. By decoupling conjugation modulation from growth dynamics, we can identify and use the determinants of plasmid mobility to fight antibiotic resistance. (B) Assembling a library of natural isolates with quantifiable rates of conjugation is a substantial undertaking. Starting from a library of 219 clinical E. coli pathogens from patient bloodstream infections, we screened for the ability to transfer -lactam resistance commonly found on plasmids native to the Enterobacteriaceae family. Approximately 25% of the carbenicillin-resistant (CarbR) isolates exhibited detectable transfer to chromosomally kanamycin (KanR) or chloramphenicol (CmR)resistant recipients. These and seven extended spectrum -lactamase (ESBL) donors were subsequently used to examine environmental and genetic determinants of plasmid mobility. (C) The diversity present in the E. coli pathogen library is maintained through conjugation screening. A phylogenetic tree of the library was constructed from 200 genome assemblies (BioProject accession nos. PRJNA290784 and PRJNA551684) to reveal the breadth of our analysis throughout each phase of screening. Genome assemblies for the remaining 19 isolates were either unavailable or of insufficient quality. E. coli strain EC958 (GenBank accession no. HG941718.1) was used as a reference genome for alignment. Isolates are color labeled by their final phase. Major multilocus sequence types (5 isolates in common) present in the library are highlighted in gray.

To address these issues, we carried out the largest-scale analysis of conjugation phenotype paired with genotype in clinical Escherichia coli pathogens known for plasmid-borne multidrug resistance. In doing so, we introduce a new method for quantifying conjugation phenotype that increases throughput and sensitivity while reducing ambiguity due to growth dynamics. In general, we find that antibiotics exert little to no effect on conjugation efficiency, with one exception displaying significant promotion in the presence of macrolides and chloramphenicol (Cm). Conversely, conjugation efficiency strongly correlates with plasmid maintenance as indicated by the incompatibility (Inc) group. As our understanding of the environmental and genetic determinants of conjugation efficiency improves, modulation of HGT may become an important new tool for the fight against antibiotic resistance and control of bacterial evolution at large.

To study conjugation modulation, we focus on a library of 219 E. coli isolates collected from patient bloodstream infections at Duke University Hospital over 2002 to 2014. The Enterobacteriaceae family of Gram-negative bacteria serves as an ideal model to study HGT. Worldwide, it causes hundreds of millions of infections per year and harbors plasmids bearing multidrug resistance, most notably extended-spectrum -lactamases (ESBLs) that cleave the most widely used class of antibiotics (18). Of these 219 isolates, 197 were chosen at random from the Duke Bloodstream Infection Biorepository (BSIB), and the remaining 22 were chosen for multidrug resistance.

We first screened the isolates for kanamycin (Kan) and Cm susceptibility to contrast with established MG1655 E. coli plasmid recipients with Kan or Cm resistance (Fig. 1B). All but 18 (8%) isolates were susceptible to at least one antibiotic, with 69 (32% total, 25% random) exhibiting resistance to Kan (50 g/ml) and 31 (14% total, 13% random) exhibiting resistance to Cm (50 g/ml). With Kan or Cm susceptibility established for each isolate, we screened for the ability to transfer -lactam resistance to susceptible recipient E. coli. Of the Kan- or Cm-susceptible isolates, 143 were found to be resistant to carbenicillin (100 g/ml; Carb). Clinical data from the BSIB indicating susceptibility to -lactam antibiotics other than Carb were used to infer Carb susceptibility for 51 isolates. The 143 Carb-resistant isolates were then tested for the ability to generate Carb- and Cm/Kan-resistant transconjugants under dual-antibiotic selection. Subsequent rounds of dilution and repeat selection were performed to ensure that any growth under dual selection was from transconjugants, instead of donors or recipients. Of the 143 Carb-resistant isolates tested, 35 (24% total, 25% random) were capable of producing Carb- and Cm/Kan-resistant transconjugants under the experimental conditions. Phylogenetic analysis revealed that much of the genetic diversity present in the starting library was maintained throughout screening (Fig. 1C). Only plasmid-free recipients were used to prevent incompatibility issues with unknown isolate plasmids and retrotransfer, which generates two transconjugants per conjugative pairing (19).

In the absence of growth dynamics, the conjugation efficiency (), or the rate constant of conjugation, can be determined as=T/(DRt)where D, R, and T, respectively, represent the densities of the donor, recipient, and transconjugant populations after a short incubation time (t) (9). This relationship can be disrupted via selection (e.g., media and antibiotics) that leads to differential growth or death (Fig. 1A). To avoid these confounding factors, we restrict growth during conjugation (fig. S1). Under these conditions, D and R can be readily determined from starting cultures, which poses no technical challenges.

Quantifying T after incubation traditionally relies on selective plating from mixed culture, which is error prone and tedious. Relatively small T and variation over multiple orders of magnitude make this more challenging, and restricting growth exacerbates these issues. To overcome these limitations, we developed a simple, yet robust method that allows transconjugant outgrowth for improved quantification. Consider the exponential growth of the transconjugant starting from an initial density of T0. T0 is uniquely related to , the time for the population to reach a set threshold TClnT0=lnTCwhere is the specific growth rate (Fig. 2A). With proper calibration, this relationship provides a high-throughput approach to quantify T0 by tracking bacterial growth via optical density (OD) in a plate reader. Experimentally, we establish a standard curve relating T0 and by growing transconjugant cultures from known starting densities. The standard curve is then used to determine T0 in samples subjected to the same growth conditions. For the same TC, the standard curves for different transconjugants (generated from different donors, but the same recipient) were highly similar to each other, reflecting a similar for these strains (fig. S2A). For the same transconjugant, we found quantification to be robust to the choice of OD thresholds that fall in the logarithmic growth phase (fig. S2B).

(A) The principle of time to threshold quantification. Consider the exponential growth of the transconjugant from an initial density T0 (top panel). The time () required for the population to reach a set threshold (TC) is uniquely determined by T0 and the specific growth rate (). This defines a log-linear relationship between T0 and : lnT0 = ln TC (bottom panel). (B) Quantification of T0 is complicated by the presence of donor and recipient cells. Top panel: Although strong antibiotic selection is applied against donor and recipient cells during transconjugant outgrowth, death is not instantaneous (i.e., conjugation may still occur). Bottom panel: Modeling reveals conjugation of variable efficiency () during outgrowth causes a deviation from the log-linear relationship. This effect is amplified with smaller T0, where transconjugants produced from outgrowth conjugationnot outgrowth alonemay comprise a sizeable proportion of the total transconjugant population. (C) Correcting for outgrowth conjugation. Top panel: The growth contribution from the transconjugant alone can be approximated by the difference (N) between the growth curves originating from the conjugation mixture (T0 > 0) and conjugation control (T0 = 0). Darker curves represent higher T0. Bottom panel: Using N, the log-linear relationship between T0 and is maintained even in the presence of conjugation during outgrowth. (D) Applying the time to threshold method to experimental data. T0, spanning six orders of magnitude, maintains a strong correlation (R2 > 0.99) with from a OD threshold. Darker curves represent higher T0.

The reliability of the standard curve depends on a critical assumption: All the growth originates from the transconjugants at time zero. This can be approximated by imposing strong double selection to suppress growth of donor and recipient cells during outgrowth. However, this suppression is not instantaneous, and new transconjugants can still be produced through conjugation (Fig. 2B).

To examine this contribution, we built a kinetic model that accounts for growth and conjugation dynamics during T outgrowth. In the absence of conjugation during outgrowth ( = 0), the model predicts a linear relationship between lnT0 and , similar to the case where exponential growth is assumed (Fig. 2A). At > 0, the correlation deviates from the log-linear relationship, where the same T0 would correspond to a smaller than what would be expected for = 0. A larger leads to a larger deviation. Under this condition, a given value of would lead to an overestimate of T0 if the log-linear relationship is directly used. However, we found that the deviation from outgrowth conjugation can be eliminated by subtracting the growth curve produced by parents mixed only at the start of outgrowth, yielding N value (Fig. 2C). The early phase of N provides an approximation of T0 growth in the absence of outgrowth conjugation, and simulated standard curves established using N do not significantly deviate from the log-linear correlation even in the presence of substantial outgrowth conjugation. Experimental results using OD to approximate N emulate the model, and displays a strong log-linear correlation with T0 over multiple orders of magnitude (Fig. 2D and fig. S2).

Together with seven previously identified ESBL donors (20), we measured the effect of antibiotics on conjugation in clinical E. coli pathogens (Fig. 3). We display the difference in time to threshold () between antibiotic and no-antibiotic control conditions to better reflect conjugation effects across isolates and minimize unnecessary data processing. The absolute magnitude of is the result of many variables that affect growth rate (e.g., conjugation and media conditions). Five antibiotics with different mechanisms of action were tested, covering inhibition of translation, DNA replication, and cell wall synthesis. Three sublethal concentrations were used, based on the 50% inhibitory concentrations (IC50) of the susceptible recipients, to capture concentration-dependent effects (9). Donor minimum inhibitory concentrations (MICs) and IC50s are shown in fig. S3A and table S3. We erred on the side of concentrations too low for the multidrug-resistant pathogens to ensure the survival of the recipients and subsequent transconjugants. Because of experimental constraints chosen to restrict background conjugation and growth dynamics, donors with conjugation efficiencies less than 1016 produced too few transconjugants for quantification.

The effect of five antibiotics on conjugation in clinical E. coli pathogens was assessed via the time to threshold method. Antibiotics of differing therapeutic mechanism were dosed in three concentrations (0.5, 1, and 2) based on 50% inhibitory concentrations for a MG1655 E. coli recipient standard. IC50 values for Carb, Cm, Kan, erythromycin (Ery), and Norf were as follows: 1.91, 1.92, 2.13, 20.20, and 0.05 g/ml. Displayed are averages of triplicate measurements SE, and normalized by subtracting the no-antibiotic control . Promotion of conjugation is indicated by < 0, while > 0 indicates inhibition. Only GN02766 displayed major modulation of conjugation when exposed to Ery (all concentrations, P < 0.01, Tukey post hoc test) and Cm (2 concentration, P < 0.05). Results from two separate GN02766 experiments are shown.

A global analysis of variance (ANOVA) revealed significant effects for both antibiotic isolate [F(94,1374) = 4.96, P < 0.0001] and antibiotic concentration isolate [F(282,999) = 2.28, P < 0.0001] interactions, prompting post hoc testing via Tukey post hoc test. We find that the majority of pathogen donors display little to no significant antibiotic modulation of conjugation, and where there is statistically significant , it corresponds to approximately less than a fivefold change in transconjugants. In addition, no correlation was seen between donor IC50 and (fig. S3B). However, isolate GN02766 exhibited a drastic increase in conjugation when exposed to certain antibiotics. GN02766 produced ~3.5-fold more transconjugants in the presence of 2 IC50 of Cm [t(7.5) = 3.7, P < 0.05, Welchs modified t test], while all concentrations of erythromycin (Ery) yielded up to 31-fold more transconjugants [t(8.5) = 18, P < 0.0001] (fig. S4A). Of the five antibiotics tested, only Cm and Ery are considered bacteriostatic and both inhibit translation via the 50S ribosomal subunit, suggesting a common mechanism. Kan, which also inhibits translation, did not have an effect, possibly due to bactericidal effects, targeting the 30S ribosomal subunit, or concentration dependence.

To distinguish a general bacteriostatic effect from a macrolide- and phenicol-specific mechanism, we retested GN02766 with azithromycin (Az) and sulfamethoxazole (Sm). Solvent- and donor-recipient strain interactions were also tested and ruled out (fig. S4B). Also a macrolide, Az differs from Ery in its 15-membered ring structure. Sm is bacteriostatic, but differs from Cm and Ery in mechanism of action by inhibiting folate and, subsequently, DNA synthesis. Az produced a virtually identical ~31-fold increase in transconjugants to Ery [t(8.4) = 15.5, P < 0.0001], while Sm produced no significant effect [t(2) = 0.04, P = 0.76] (fig. S4C). Together, these results suggest macrolide- and, to a lesser degree, phenicol-specific promotion of conjugation in GN02766.

To reveal plasmid genotype and identify features associated with antibiotic modulation and conjugation efficiency, we performed whole-genome sequencing on 19 isolates of varying conjugative phenotypes (BioProject no. PRJNA551684). For large plasmids, standard plasmid purification kits yielded poor results, and sequence assembly from short reads has been shown to be difficult. Instead, we used long-read sequencing from Pacific Biosciences (PacBio) capable of accurately discerning mobile elements from the chromosome. As predicted from empirical findings, plasmid-borne -lactamases were detected in each isolate. A summary of sequencing results can be found in table S2, complete with plasmid number, size, replicon (Inc), mobility relaxase (MOB), and identified resistances present in each isolate.

GN02766 was found to harbor two plasmids: p2766-1, a 137-kb plasmid identified as IncFIB/IncFII/Col156, and a 29-kb plasmid without designation. Without identifiable MOB or transfer (tra) machinery on the 29-kb plasmid, only p2766-1 appears to be mobile and carries a -lactamase, blaSHV, relevant to our conjugation assay. By comparing the plasmids of isolates displaying no antibiotic modulation to p2766-1, we can identify unique features that may give insight into how macrolide and phenicol antibiotics promote conjugation. Here, we show 24 of these plasmids that bear the greatest similarity to p2766-1 (nucleotide identity, 70%), although much diversity remains (Fig. 4). Much of the tra region for conjugation was conserved across plasmids with traJ, a key activator of tra gene expression, as a notable exception. We also aligned plasmid sequences to p168-1, the closest match to p2766-1 that displayed no antibiotic modulation, to see what common features p2766-1 might lack (fig. S5). No major commonalities among the majority of plasmids appear to be lost, suggesting the conjugation phenotype of p2766-1 may be gained instead.

Plasmid sequences from strains displaying no antibiotic modulation were aligned to p2766-1 via BLASTn and BLAST Ring Image Generator (BRIG) (47). Nucleotide identity 70% is indicated by a band colored according to the Inc group, with darker shading corresponding to higher sequence match. Blank regions indicate <70% nucleotide identity. Inner GC content plots, size map, and outer coding sequences (CDSs) are for p2766-1. Antibiotic resistance genes are highlighted in red, and transposon repeat region in gray. Notable features include five-plasmid maintenance systems (pemKI, relBE, hok-sok, srnBC, and parAB), a mobilized enterotoxin and colicin J receptor operon (cjrABC-senB), and five consecutive tnpA transposon repeats carrying blaSHV.

There are several features of note on p2766-1: five plasmid maintenance systems, a mobilized enterotoxin and colicin J receptor operon, and five consecutive tnpA transposon repeats. Of the five plasmid maintenance systems, four function through addiction (pemKI, relBE, hok-sok, and srnBC), with toxins that kill daughter cells if they lack the plasmid-encoded antitoxin. For comparison, ESBL-producing strains only have 2.38 addiction systems on average with a range of 0 to 6 (21). The fifth maintenance system, parAB, aids in plasmid segregation (22). In common with two other IncFIB/FII/Col156 plasmids, p2766-1 also includes cjrABC and senB, which play important roles in E. coli pathogenesis (23). Unique to p2766-1 is a repetitive region of five consecutive tnpA transposon repeats, each bearing a deoR, blaSHV, recF, and truncated lacY gene, respectively, encoding a transcriptional repressor of sugar metabolism (24), ESBL, DNA recombination and repair protein, and -galactoside permease. This repetitive region is genuine as we see no decrease in sequence coverage indicative of assembly error (fig. S6). It is particularly interesting that deoR is implicated in limiting plasmid copy number (25), and recF facilitates recombination (26, 27) and mutagenesis (28). A closely related IS26-flanked blaSHV-5 amplicon was found to spread via recombination, not transposition, with up to 11 consecutive amplicons forming under high -lactam antibiotic stress (29).

The conjugation phenotypes we observed with clinical E. coli pathogens can arise from the plasmids, chromosomes, or both. To control for chromosomal effects, we used Kan-susceptible DA28102 transconjugants (denoted as strain #T) as donors to Kan-resistant fAYC002 recipients. With plasmids as the only differences between the transconjugants, any change in conjugation efficiency may therefore be attributable to the plasmids themselves. In this way, the macrolide promotion seen in GN02766 appears to be transferrable, with 0.5 and 1 IC50 of Ery significantly reducing (P < 0.0001 and P < 0.05, respectively, Tukey post hoc test) when 2766T is used as a donor (fig. S7A). No effect was seen with other DA28102 transconjugants, further supporting a p2766-1based mechanism (fig. S7B). Donor, recipient, and growth conditions likely play a role, however, as the degree of macrolide promotion was diminished in 2766T.

Compared to the maximum 31-fold change we saw with antibiotics, the baseline conjugation efficiencies of plasmids have the potential to differ over several orders of magnitude. Even relatively minor changes, such as growth stage or nutrient concentration, can cause orders of magnitude shifts in conjugation efficiency (9, 10, 30). Here, we focus on the origin of these more fundamental distinctions between conjugative plasmids. Plasmids are typically classified by two major systems: Inc group and MOB relaxase. Inc groups are based around plasmid maintenance (e.g., replication controls), where two plasmids of the same Inc group could not be stably maintained in the same cell (31). MOB relaxase typing, centered on the protein that nicks oriT to initiate conjugative transfer, was proposed to avoid problems in the Inc system, such as multiple replicons or maintenance systems that differ greatly in how they work (32).

MOB relaxases are thought to accurately represent tra machinery based on high congruence between their phylogenetic trees (32). Therefore, we wondered whether MOB relaxase might correlate with conjugation efficiency with the donor, recipient, and environment held constant. However, we find that Inc groups are more predictive of a plasmids conjugation efficiency than MOB relaxase [F(6,53) = 111.6, P < 0.0001 versus F(2,57) = 1.26, P = 0.291, respectively, ANOVA; Fig. 5). The strong correlation between the Inc group and conjugation efficiency remains when the 2766T outlier is removed [F(5,48) = 62.36, P < 0.0001]. Inc groupings were made at the most general level (i.e., IncF includes IncFI, FII, etc.) for plasmids carrying a -lactamase marker by which we measured conjugation. Given the apparent difference between the IncF/Col and IncF groups, we paid particular attention to mobilizable colicin plasmids that can transfer alongside the -lactamase (i.e., from GN05696 to 5696T and beyond). Further subdivisions in Inc groups and MOB types may yield greater resolution between conjugation efficiencies. Our results suggest that the factors involved in plasmid maintenance play a more significant role in its transfer than previously thought.

Plasmids carrying -lactamases from clinical E. coli pathogens were classified by Inc grouping and MOB relaxase families. To eliminate host effects, conjugation efficiencies were only measured using DA28102 transconjugants and the fAYC002 recipient. There is no significant difference among conjugation efficiencies when grouped by MOB relaxase (P = 0.291, ANOVA), whereas grouping by Inc is highly significant (P < 0.0001). Individual Inc groups that could not be distinguished from one another at P 0.05 are bracketed. Data were log transformed to normalize variation across orders of magnitude. Error bars represent SD from at least three replicates.

Drawing from the same fundamental principles as quantitative polymerase chain reaction, we developed time to threshold as a simple and effective new method for quantifying plasmid transfer rates in the absence of confounding growth dynamics. The time to threshold method improves upon agar plating in both throughput and sensitivity, returning transconjugant density in as little as 5 hours without the ambiguity from subjective colony counting. Amid conflicting reports for antibiotic modulation of conjugation (9, 11, 15, 16), we find little to no effect in this largest study of conjugation phenotype in clinical E. coli pathogens. The lack of a general antibiotic effect suggests that modulation, if present, arises from more specific interactions and highlights the potentially confounding impact of growth dynamics on conjugation quantification. Yet, even minor modulation of conjugation maintained over time may be sufficient to push plasmids above or below critical maintenance thresholds (7). As more conjugation inhibitors and promoters are discovered, we may begin to harness and incorporate these dynamics into prophylactic strategies that address the source of antibiotic resistance for many pathogens (5).

Isolate GN02766 is an exceptional case of conjugation modulation with the ability to spread antibiotic resistance faster in the presence of antibiotics. Through the time to threshold method, we detect up to 31-fold promotion of conjugation upon exposing GN02766 to macrolides or Cm, both of which target the 50S ribosomal subunit. We link macrolide promotion to a single IncFIB/FII/Col156 plasmid (i.e., p2766-1) bearing five plasmid maintenance systems and tnpA transposon repeats notably encoding deoR, blaSHV, and recF. Unique to p2766-1 and the conjugation promotion phenotype, deoR and recF are involved in suppressing copy number (25) and promoting recombination of plasmids, respectively. Translation inhibition from macrolides and Cm may relieve metabolic suppression from multiple copies of deoR and destabilizing oligomerization from recF (33), increasing p2766-1 copy number, tra gene expression, and, ultimately, conjugation efficiency. As the number of unique -lactamases continues to rise, the potential this transposon offers for blaSHV diversification through gene duplication is concerning (29). Both intra- and intercellularly mobile through recombination and antibiotic-promoted conjugation, this blaSHV transposon represents a threat for the evolution of antibiotic resistance and warrants further study.

Going beyond special cases, understanding the determinants underlying plasmid mobility is critical to predicting how they spread as vehicles of antibiotic resistance and HGT. By removing host and growth variables, we find that Inc groups based on plasmid maintenance appear predictive of conjugation efficiency, whereas MOB relaxase classification does not. This comes as a surprise given MOB relaxases more direct connection to conjugation (32). However, the dominance of MOBF and MOBP among E. coli isolates with detectable conjugation falls in stark contrast to the diversity of Inc groups, suggesting that MOB may dictate plasmid prevalence at a high level (31, 34). The apparent predictive power of incompatibility groups, as ubiquitous features of plasmids, could nevertheless hold considerable value for understanding gene flow through HGT networks, especially if it extends beyond E. coli and the plasmids studied herein. Knowing which plasmids and bacterial strains are most adept at mobilizing antibiotic resistance could better guide strategies to inhibit its spread and improve the life span of antibiotics (5, 7, 35).

A full description of all strains used in this study can be found in table S1.

Unless otherwise stated, donor or recipient strains were cultured at 37C in standard Luria-Bertani (LB; Miller) broth with shaking. Conjugation experiments were performed in M9 media containing casamino acid (2 mg/ml), thiamine (0.1 mg/ml), 2 mM MgSO4, 0.1 mM CaCl2, and 0.4% (w/v) glucose. We call this M9CA media in subsequent text. Rich LB or terrific broth (TB) was used to generate high cell density for subsequent conjugation in M9CA, which was used to control for growth dynamics. Shaking is applied for oxygenation, accurate OD measurements, and breaking up conjugation pili.

We screened the pathogen library for Carb, Cm, and Kan resistance to establish selection markers for conjugation quantification. The BSIB had previously collected disk diffusion data on -lactam antibiotics other than Carb, which we used to infer Carb susceptibility (CarbS) for 51 isolates. Isolates without prior data or with ambiguous resistance were inoculated in 1 ml of LB media in 96deep well plates, covered in a gas-permeable membrane, and grown overnight. Once grown, cultures were diluted 1000 into secondary 96-well plates with and without added antibiotic. Concentrations for antibiotics were as follows: Carb (100 g/ml), Cm (50 g/ml), and Kan (50 g/ml). Secondary plates were then grown for approximately 16 hours. At this point, the OD600 of each culture was measured in a plate reader. Antibiotic culture OD was normalized to corresponding no-antibiotic cultures. Resistance to each antibiotic was defined as 1% maximal growth.

The MIC, which we defined as the first antibiotic concentration to yield 10% or less of the no-antibiotic controls maximum OD600, and IC50 were also determined for plasmid donors tested for antibiotic effects on conjugation (fig. S3A and table S3). Plasmid donors were grown for 16 hours, diluted 100-fold into M9CA with antibiotic concentrations ranging from 0 to 64 g/ml, and then grown for 24 hours before taking endpoint OD600 measurements.

To find pathogens capable of conjugation, we screened Carb-resistant isolates for the ability to transfer -lactamase into Carb-susceptible recipients. Pathogen cultures were grown overnight in 1 ml of LB media with Carb (100 g/ml) in 96deep well plates covered in a gas-permeable membrane. Recipients were grown overnight in 3 ml of LB media with either Kan (50 g/ml) or Cm (70 g/ml). Pathogen isolates were then diluted 10 in LB media and regrown under similar conditions for 2 hours to enter exponential phase. Exponential-phase pathogen isolates and recipient were diluted 100 into 200 l of LB media and mixed 1:1 in a 96-well plate with dual antibiotic selection for transconjugants. Mixed cultures were then covered with 50 l of mineral oil and grown in a plate reader for 24 hours.

After 24 hours of exposure to transconjugant selection, mixed pathogen and recipient cultures that displayed growth were diluted 1000 into fresh LB media with antibiotic selection for transconjugants. These cultures were covered with 50 l of mineral oil and regrown in a plate reader for 24 hours. Cultures that repeated growth under high dilution and strong transconjugant selection were plated on agar also selecting for transconjugants. Individual colonies were isolated and grown overnight in 3 ml of LB media with transconjugant selection. These clonal transconjugant cultures were glycerol stocked for later analysis.

Donor E. coli strains were inoculated into 3 ml of TB media with Carb (100 g/ml) and grown for approximately 16 hours at 37C without shaking. An appropriate recipient MG1655 E. coli strain (CmR DA28102 or KanR fAYC002) with contrasting resistance markers was similarly grown, but with 50 g/ml selecting antibiotic and shaking. Following growth, donor cultures were diluted 10 and regrown for 2 hours to enter the exponential phase. Recipient and exponential-phase donor cultures were pelleted at 2000 relative centrifugal force (rcf) for 10 min at 25C and resuspended in M9CA media, equalizing OD600. At this point, aliquots of donor and recipient cultures were taken for quantification via agar plating and controls for outgrowth conjugation.

Donor and recipient cultures were then mixed in a 1:1 ratio for conjugation, distributed in 500-l volumes, and incubated for 1 hour at room temperature while being exposed to antibiotic or control test conditions. Antibiotic test conditions were applied in 0.5, 1, and 2 multiples of IC50s determined for the primary MG1655 E. coli recipient. IC50 values for Carb, Cm, Kan, Ery, and Norf were as follows: 1.91, 1.92, 2.13, 20.20, and 0.05 g/ml (9). These growth conditions were chosen to restrict growth during conjugation. After 1 hour, cell mixtures were vortexed to disrupt conjugation, pelleted, and resuspended in 500 l of M9CA. The separated donor and recipient conjugation control aliquots were then mixed to track outgrowth conjugation.

The experimental and outgrowth conjugation control curves must be displaced in time; otherwise, OD will not reach target OD600 thresholds. For this reason, all cell mixtures were diluted 150 in M9CA with dual antibiotic selection [Carb (100 g/ml), Cm (70 g/ml), and Kan (50 g/ml)] according to the donor-recipient pairs and then distributed three times in 150-l volumes onto a microtiter plate. Microtiter cultures were covered with 50 l of mineral oil to prevent evaporation and grown in a plate reader for 24 hours at 37C, shaking before each OD600 measurement. The 150 dilution was chosen on the basis of an estimated of ~1014 from previous growth-restricted E. coli measurements. For best results, T0 should be maximized while minimizing outgrowth . Outgrowth dilutions and temperature may need to be adjusted on a strain-by-strain basis to optimize separation between experimental and control curves. For E. coli, the most common plasmids belong to the IncF family. Therefore, to maximize T0 with the E. coli library, we used rich, buffered TB media for optimal conjugative pili formation and exponential-phase donor cultures for activation of F plasmid transfer machinery (30). Conversely, recipients are kept in stationary phase for decreased motility or cell wall modifications thought to improve pili tip searching (9, 36).

Transconjugant growth curves were passed through a moving average filter in MATLAB to reduce noise. Time to specified OD600 threshold was found via linear interpolation. OD600 thresholds were typically chosen between 0.03 and 0.05 in early exponential phase to reduce background noise, maintain the cell density:OD relationship, and lessen postantibiotic effects (37). Within this range, changes in OD threshold had little effect on the correlation between and T0 (fig. S2B).

Transconjugant cultures were grown following the time to threshold protocol to accurately recreate postconjugation outgrowth conditions. Once resuspended in M9 media with Carb (100 g/ml) and Cm (70 g/ml), the cultures were serially diluted by 107 and plated on LB agar to determine T0 via colony-forming units (CFUs). These dilutions were then covered in 50 l of mineral oil and grown in a plate reader as before for 24 hours. With known T0, we constructed standard curves for each transconjugant strain by calculating from growth curves at varied OD thresholds. We find that defined M9 with Carb (100 g/ml) and Cm (70 g/ml) antibiotic concentrations minimizes standard curve variation across strains.

Time to threshold results () were normalized by subtracting from the no-antibiotic control yielding a value. An outlier for both ESBL41 and ESBL168 was removed due to unambiguous plate reader and experimental error, respectively, to preserve data integrity. Triplicate measures were parsed with ANOVA in R to reveal significant global interactions among strain, antibiotic, and concentration variables. Tukey post hoc test was performed for significant interactions. All tests are two tailed, and all replicates are technical unless indicated otherwise.

We selected 19 strains for whole-genome sequencing covering a range of conjugation dynamics. Genomic DNA was extracted using the QIAGEN MagAttract highmolecular weight DNA kit (catalog ID: 67563) from cultures grown for 16 hours until a density of approximately 109 cells/ml. DNA libraries were prepared according to PacBios recommendations and sequenced using the PacBio Sequel system.

All samples were assembled and polished using the PacBio SMRT Analysis assembly pipeline (SMRTLink version 5.1.0.26412), which uses HGAP 4 for assembly and Quiver for assembly polishing. Default parameters were applied, with the following exceptions: genome length was set to 5 Mb, the aggressive option was set to true, no read quality filters were applied, and the default falcon configuration parameters were supplanted with the following parameters: pa_DBsplit_option = -x500 -s200; ovlp_DBsplit_option = -x500 -s200. For samples with initial suboptimal assemblies, seed coverage was modified to increase the proportion of corrected reads. Seed coverage was set to 60 for ESBI168, GNO2448, and GNO4540, and 35 for GNO2766.

For constructing the phylogenetic tree, single-nucleotide polymorphisms (SNPs) were identified from genome assemblies (BioProject accession nos. PRJNA290784 and PRJNA551684) following the North Arizona SNP Pipeline (NASP) pipeline (38) using E. coli strain EC958 (GenBank accession no. HG941718.1) as a reference. Duplicated regions of the reference genome, including repeat regions and multiple gene copies, were determined by aligning the reference sequence to itself using the NUCmer-3.23 (39). SNPs that fell within these duplicate regions were excluded from further analysis to avoid false SNP calls due to ambiguous read alignment. Each query genome assembly was aligned to the reference with NUCmer-3.23. The best SNPs in all genomes compared to the reference were concatenated in a matrix. Phylogenetic trees were inferred using the maximum likelihood (ML) method available in RAxML (40, 41). This returned the best-found tree from 100 replicates inferred using the general time-reversible substitution model.

For Inc typing, the plasmid sequences were queried against a locally downloaded version (retrieved 22 May 2018) of the PlasmidFinder database (http://www.genomicepidemiology.org), using the recommended percentage coverage threshold of 60% and a more stringent percentage identity and e-value thresholds of 90% and 0.00001, respectively (42). MOB typing was performed as previously described, and default value was chosen for all parameters (43). Specifically, the e-value threshold of each MOB type was chosen as follows: MOBC, 0.001; MOBF, 0.01; MOBH, 0.01; MOBP, 1; MOBQ, 0.0001; and MOBV, 0.01. In addition, 247,882 protein sequences were extracted from a National Center for Biotechnology Information dataset of 6952 complete Enterobacteriaceae plasmids (44) and were compiled into a database in combination with the sequences of 2423 antibiotic resistance proteins from ResFinder database (retrieved 22 May 2018) (http://www.genomicepidemiology.org) (45) as predicted by prodigal v2.6.3 (46). Genome assemblies were further annotated using Prokka v1.13 (47) against the above compiled protein database. For comparison, plasmids were aligned to one another via BRIG, displaying sequence matches with nucleotide identity 70% (48).

Transconjugant conjugation was performed similarly to the time to threshold protocol with a few exceptions. Transconjugant donors were grown with shaking as DA28102 displays poor growth otherwise and fAYC002 was the sole recipient used. Donor, recipient, and second-generation transconjugant cell densities were quantified through LB agar plating and CFU counting.

Acknowledgments: We thank D. Anderson for contributing clinical isolates. We also thank the Duke Center for Genomic and Computational Biology, Duke Sequencing core facility, Duke Bioinformatics core facility, and J. Modliszewski, N. Devos, and G. Alexander Jr. specifically for their support with whole-genome sequencing of the isolates. Funding: L.Y. acknowledges support from the NIH (R01GM098642 and R01AI125604), Army Research Office (W911NF-14-1-0490), and the David and Lucile Packard Foundation. J.H.B. acknowledges a graduate fellowship from the NSFs IBIEM Training Grant. Author contributions: J.H.B. designed and performed the modeling and experimental analyses, interpreted the results, and wrote the manuscript. A.D. developed the analysis pipeline for time to threshold measurements and assisted with conjugation experiments. L.C., W.S., and M.X. processed, annotated, and analyzed the whole-genome sequencing results. A.J.L. conceived the research and assisted with the manuscript revisions. J.T.T. and V.G.F.J. provided clinical isolates and assisted with manuscript revisions. L.Y. conceived the research and assisted with the modeling, experimental design, data analyses, and manuscript revisions. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Genomic sequence data are available from GenBank with BioProject accession no. PRJNA551684. Additional data related to this paper may be requested from the authors.

Read the original:
Environmental and genetic determinants of plasmid mobility in pathogenic Escherichia coli - Science Advances

Read More...

America’s most widely consumed cooking oil causes genetic changes in the brain – University of California

January 26th, 2020 4:44 am

New UC Riverside research shows soybean oil not only leads to obesity and diabetes, but could also affect neurological conditions like autism, Alzheimers disease, anxiety, and depression.

Used for fast food frying, added to packaged foods, and fed to livestock, soybean oil is by far the most widely produced and consumed edible oil in the U.S., according to the U.S. Department of Agriculture. In all likelihood, it is not healthy for humans.

It certainly is not good for mice. The new study, published this month in the journal Endocrinology, compared mice fed three different diets high in fat: soybean oil, soybean oil modified to be low in linoleic acid, and coconut oil.

The same UC Riverside research team found in 2015 that soybean oil induces obesity, diabetes, insulin resistance, and fatty liver in mice. Then in a 2017 study, the same group learned that if soybean oil is engineered to be low in linoleic acid, it induces less obesity and insulin resistance.

However, in the study released this month, researchers did not find any difference between the modified and unmodified soybean oils effects on the brain. Specifically, the scientists found pronounced effects of the oil on the hypothalamus, where a number of critical processes take place.

The hypothalamus regulates body weight via your metabolism, maintains body temperature, is critical for reproduction and physical growth as well as your response to stress, said Margarita Curras-Collazo, a UC Riversideassociate professor of neuroscience and lead author on the study.

The team determined a number of genes in mice fed soybean oil were not functioning correctly. One such gene produces the love hormone, oxytocin. In soybean oil-fed mice, levels of oxytocin in the hypothalamus went down.

The research team discovered roughly 100 other genes also affected by the soybean oil diet. They believe this discovery could have ramifications not just for energy metabolism, but also for proper brain function and diseases such as autism or Parkinsons disease. However, it is important to note there is no proof the oil causes these diseases.

Additionally, the team notes the findings only apply to soybean oil not to other soy products or to other vegetable oils.

Do not throw out your tofu, soymilk, edamame, or soy sauce, said Frances Sladek, a UC Riverside toxicologist and professor of cell biology. Many soy products only contain small amounts of the oil, and large amounts of healthful compounds such as essential fatty acids and proteins.

A caveat for readers concerned about their most recent meal is that this study was conducted on mice, and mouse studies do not always translate to the same results in humans.

Also, this study utilized male mice. Because oxytocin is so important for maternal health and promotes mother-child bonding, similar studies need to be performed using female mice.

One additional note on this study the research team has not yet isolated which chemicals in the oil are responsible for the changes they found in the hypothalamus. But they have ruled out two candidates. It is not linoleic acid, since the modified oil also produced genetic disruptions; nor is it stigmasterol, a cholesterol-like chemical found naturally in soybean oil.

Identifying the compounds responsible for the negative effects is an important area for the teams future research.

This could help design healthier dietary oils in the future, said Poonamjot Deol, an assistant project scientist in Sladeks laboratory and first author on the study.

The dogma is that saturated fat is bad and unsaturated fat is good. Soybean oil is a polyunsaturated fat, but the idea that its good for you is just not proven, Sladek said.

Indeed, coconut oil, which contains saturated fats, produced very few changes in the hypothalamic genes.

If theres one message I want people to take away, its this: reduce consumption of soybean oil, Deol said about the most recent study.

Go here to read the rest:
America's most widely consumed cooking oil causes genetic changes in the brain - University of California

Read More...

Ice hockey: Belfast Giants give boy with genetic disorder ‘reason to fight’ – BBC News

January 26th, 2020 4:44 am

Media playback is unsupported on your device

"Is my blood teal?"

It may sound like a surprising question for a doctor to hear - but this isn't just any patient. This is Blake McCaughey, a Belfast Giants superfan.

The 12-year-old, from Tandragee in County Armagh, has a rare genetic disorder that means he will spend the foreseeable future in hospital, hooked up to pumps, for up to 20 hours a day.

But ice hockey has become "the reason he fights so hard through all these challenges".

He spends hours every day watching the sport from his hospital bed, which has been brightened up with teal pillows, in support of his beloved team.

When player Spiro Goulakos broke his ice hockey stick, it was used to make Blake a new pair of crutches.

"For Blake, life is hockey - everything that drives him through rough times will be about hockey and the Giants," his mum, Christine, told BBC News NI.

Blake was born with two chromosome deletions and abnormal muscle fibres.

By the time he was 16 months old, he had had 33 hospital admissions and battled pneumonia 19 times. Since then, he has been designated "nil by mouth".

In May 2017, he had open-heart surgery.

"When he was coming round from surgery, one of the Belfast Giants was there, holding his hand," said Christine.

Blake recovered well but, two years later, his health declined: His gut and bowel stopped absorbing nutrients and his heart rate, blood pressure and body temperature dangerously lowered.

Just last week he had more surgery to help with feeding and he will remain in hospital until he has gained weight.

"When Blake has a bad day, a simple photo or video call from one of his hockey buddies helps him keep fighting," said Christine.

"The Giants have always been a rock to Blake and us, and Blake has no bones in saying that Belfast Giants head coach Adam Keefe is his best mate, although he doesn't like Adam getting cross on game nights on the bench."

When Blake is well enough to leave the hospital, watching ice hockey is always at the top of his to-do list. It's even better when he gets to go with his little sister Pixie.

"He hates to miss a game," said Christine.

"Unlike most 12 year olds, Blake will never get to experience playing hockey but, with friends like the Belfast Giants, they make the impossible very possible and on a few occasions have had Blake out of his wheelchair, pull on the skates and be held whilst he skates in the SSE Arena."

His love for ice hockey has even caught the attention of other teams in the Elite Ice Hockey League (EIHL), the UK's premier competition, who send him videos and messages of love and support.

"Social media has brought us many friends on our journey from far and wide, and especially the hockey community," said Christine.

"Every team in the EIHL has looked after Blake so well and he's got good friends on every team. They have all reached out when Blake has needed a little encouragement along the way.

"Players for the Giants come and go, depending on their contracts, but some of our closest friends have been found through the Giants and no matter where they are in the world, they still keep very much in touch," she added.

"We use social media to spread awareness of Blake's condition and to share his amazing attitude to life, the strength and courage he has pulls us all through. His personality is one of a kind.

"When you meet him for the first time, you will see a shy little boy in a wheelchair but he's an absolute character and fond of the girls, especially nurses and doctors!

"He is a mischievous, fun-loving, hockey-crazed boy who spends hours watching hockey, talking hockey and even sleeps in hockey bedding.

"Blake loves everything teal and they are the reason he fights so hard through all these challenges."

Go here to read the rest:
Ice hockey: Belfast Giants give boy with genetic disorder 'reason to fight' - BBC News

Read More...

Genetic Non-Discrimination Bill Advances in Florida – The National Law Review

January 26th, 2020 4:44 am

Thursday, January 23, 2020

Florida could be the first state to deny life and long-term care insurers access to genetic test results. Under a new bill titled Genetic Information for Insurance Purposes (HB 1189), life insurers and long-term care insurers are prohibited from canceling, limiting, or denying coverage, or establishing differentials in premium rates based on genetic information. In addition, HB 1189 would prevent life insurers and long-term care insurers from requiring or soliciting genetic information, using genetic test results, or considering a person's decisions or actions relating to genetic testing in any manner for any insurance purposes.

On Jan. 16, the Florida House Health & Human Services Committee passed HB 1189 without any debate. The bill is now being reviewed by the Commerce Committee, which will have to clear the bill before it would be ready to go to the full House.

HB 1189 is sponsored by Representative Chris Sprowls, the incoming Speaker-designate. It is the only bill he has filed this year. In the Senate, the bill is sponsored by Kelli Stargel, who is part of Senate leadership. Given HB 1189s sponsors, the issue will likely be a high profile one, and will have a good chance of passing in the next year or two.

Existing federal law, the Genetic Information Nondiscrimination Act (GINA), protects Americans from discrimination in health insurance, employment decisions, and employee benefit decisions on the basis of genetic information. Under GINA, U.S. insurance companies and health plans (including both group and individual insurers, as well as federally regulated plans) are prohibited from:

looking at predictive genetic information or genetic services before enrollment;

requesting or requiring that individuals or their family members take a genetic test;

restricting enrollment based on genetic information;

changing premiums based on genetic information.

GINA, however, does not cover life, long-term care, or disability insurance providers. As a result, those companies can ask about health, family history of disease, or genetic information, and reject those that are deemed too risky.

2020 Greenberg Traurig, LLP. All rights reserved.

The rest is here:
Genetic Non-Discrimination Bill Advances in Florida - The National Law Review

Read More...

GyanSys Selected by AgReliant Genetics as the Primary Partner for Their Implementation of SAP S/4HANA as Part of Their Digital Transformation -…

January 26th, 2020 4:44 am

CARMEL, Ind., Jan. 24, 2020 /PRNewswire/ --AgReliant Genetics, a leader in seed research, production and provider of seed solutions, signed a contract with GyanSys Inc. ("GyanSys"), a leading IT services provider headquartered in Indiana, to implementSAP S/4HANA on HANA Enterprise Cloud (HEC) as part of their digital transformation journey to replace their legacy ERP systems.

Steve Thompson, CIO of AgReliant Genetics "GyanSys led our team to conduct S/4HANA Best Practice workshops, gap analysis, and recommended the right SAP software bill-of-materials. AgReliant is excited to start our digital transformation journey partnering with GyanSys to build a scalable digital core for our Finance, Purchasing, Planning, Sales, Manufacturing, and Warehouse Management systems."

Rajkishore Una, President & CEO of GyanSys "GyanSys is committed to successfully deliver AgReliant Genetics' new SAP environment with our global delivery approach and our best practice-led implementation methodology. We are bringing our expertise in SAP S/4HANA digital core, alongside BPC, EWM, aATP, Manufacturing for Planning & Scheduling, and Analytics Cloud, for AgReliant to derive the most value from this strategic investment."

About AgReliant Genetics:

AgReliant Genetics offers corn, soybean, sorghum, and alfalfa seed solutions to farmers through their product brands. Contact your local AgriGold, LG Seeds, or PRIDE Seeds representative for more information.

Learn more about AgReliant Geneticsat http://www.agreliantgenetics.com.

About GyanSys Inc.:

GyanSys is a mid-tier global systems integrator specializing in SAP, Salesforce, Microsoft, and ServiceNow Platforms to improve the Sales, Finance, Supply Chain, Manufacturing, Operations, and HR business processes to support digital transformation.

Headquartered in Indiana, GyanSys was founded in 2005 and has approximately 1,000+ professionals globally serving 125+ customers across various industries, including the manufacturing, automotive, high-tech, CPG, and life sciences industries.

For more information about GyanSys, visit http://www.gyansys.com.

For press inquiries and more information, contact:Cliff SaitoDigital Marketing ManagerE-mail: cliff.saito@gyansys.com

Related Images

gyansys-logo.png GyanSys Logo

Related Links

AgReliant Genetics Website

GyanSys Website

SOURCE GyanSys

Home

See the original post:
GyanSys Selected by AgReliant Genetics as the Primary Partner for Their Implementation of SAP S/4HANA as Part of Their Digital Transformation -...

Read More...

Genetic test developed to predict onset of glaucoma – The Siasat Daily

January 26th, 2020 4:44 am

Washington: A group of researchers from Australia has formulated a genetic test that could detect peoples susceptibility towards developing glaucoma, which is a debilitating ocular disease that can potentially make its sufferers go blind.

The team of scientists suggests that there are 107 genes that are responsible for the onset of this condition.

They are looking forward to 20,000 peoples participation in their Genetics of Glaucoma Study in order to help them find more genes involved in the disease.

Glaucoma is characterised by progressive damage and degeneration of the optic nerve which also causes gradual loss of vision. It is the leading cause of irreversible blindness worldwide and is predicted to affect 76 million people by 2020.

There is still no proven cure for the disease, but treatment can reliably slow or halt deterioration in most cases. Up to 50 percent of those affected are not even aware.

Stuart MacGregor, lead researcher and the head of QIMR Berghofers Statistical Genetics Group, Associate Professor, said that identifying new genes allowed them to develop a glaucoma polygenic risk score (PRS) that can predict who is likely to get the eye disease.

Glaucoma is a genetic disease and the best way to prevent the loss of sight from glaucoma is through early detection and treatment, MacGregor defined.

Our study found that by analysing DNA collected from saliva or blood, we could determine how likely a person was to develop the disease and who should be offered early treatment and/or monitoring, he added.

He also feels that unlike existing eye health checks that are based on eye pressure or optic nerve damage, the genetic test can be done before damage begins so that regular screening can be put in place.

Clinical lead researcher and academic head of the Department of Ophthalmology at Flinders University, Professor Jamie Craig, said that the study results gave hope that mass screening for glaucoma could be offered in the future.

There are Australians who, if theyd had appropriate treatment a few years earlier, wouldnt have gone blind, said Professor Craig, who is also a consultant ophthalmologist.

One in 30 Australians has glaucoma, but most people only find out they have it when they go to the optometrist because they are losing vision, or for a general eye check, shares Craig, continuing, Early detection is paramount because existing treatments cant restore vision that has been lost, and late detection of glaucoma is a major risk factor for blindness.

He said that glaucoma can arise at any age but most of those affected are in their 50s or older, so their aim is to offer blood tests to people of that age to find out if they are at risk, and then hopefully act on it.

This test is likely to be helpful in identifying those who would benefit from a more aggressive intervention such as surgery rather than simple eyedrops.

The researchers are hoping to get in touch with people with a family history of the disease. We want to know who will get glaucoma, and for those who are susceptible, we want to be able to pinpoint at what age theyre going to get it, said Associate Professor MacGregor.

The researcher concluded, That would allow us to develop a personalised approach for earlier treatment of high-risk individuals, and means people at lower risk could have less intensive monitoring and treatment. This would have benefits for patients, doctors and the health care system with reduced interventions and reduced costs.

View original post here:
Genetic test developed to predict onset of glaucoma - The Siasat Daily

Read More...

‘Genetic mutations must be regulated’ – Telangana Today

January 26th, 2020 4:44 am

Hyderabad: Creating super humans through genetic mutations is a red line that should not be crossed, said Prof. Virjinijus Siksnys, the biochemist who developed the gene-editing tool CRISPR, here on Friday.

CRISPR is a very powerful technology and people are now just testing boundaries of this technology. Scientists, in general, agree that you can use the gene-editing tool to correct mutations to cure diseases. But, improving humans is a Pandoras Box, which should be avoided, he said.

Prof Sriksnys, a biochemist from Institute of Biotechnology, Vilnius University, Lithuania, while delivering Dr Manohar VN Shirodkar Memorial Lecture of Telangana Academy of Sciences (TAS) at IICT, said there was a definite need for regulatory authorities from the US and European Union to come together and put in place a framework for the CRISPR technology.

Many discussions are ongoing on having regulations in the US and EU. Hopefully, in the coming few years, there will be some regulations in place. CRISPR is a tool that can be used for different applications and it depends on us on how we are going to use it, he said.

CRISPR enables geneticists to edit parts of the genome by removing and adding or altering sections of the DNA sequence. I believe such mutations can be introduced in plants very quickly. Usually, it takes a long time to develop better plant varieties. But, CRISPR technology can help speed up the process of generating better plant varieties, he said.

Senior office-bearers of TAS including its president Prof K Narasimha Reddy, former president Dr CH Mohan Rao, IICT Director S Chandrasekhar, CCMB Director RK Mishra and students from different schools were present.

Now you can get handpicked stories from Telangana Today on WhatsApp / Telegram everyday. Click these links to subscribe and save this number 9182563636 on your contacts.

Click to follow Telangana Today Facebook page and Twitter

Read more:
'Genetic mutations must be regulated' - Telangana Today

Read More...

Page 732«..1020..731732733734..740750..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick